Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
29 Articles
Current state of cytopathology residency training: a Korean national survey of pathologists
Uiju Cho, Tae Jung Kim, Wan Seop Kim, Kyo Young Lee, Hye Kyoung Yoon, Hyun Joo Choi
J Pathol Transl Med. 2023;57(2):95-101.   Published online March 14, 2023
DOI: https://doi.org/10.4132/jptm.2023.01.06
  • 114 View
  • 6 Download
AbstractAbstract PDFSupplementary Material
Background
Although the Korean Society for Cytopathology has developed educational goals as guidelines for cytopathology education in Korea, there is still no systematic approach to cytopathology education status for pathology residents. Furthermore, satisfaction with cytopathology education and with the outcome of the current training/educational program has not been investigated in Korea. This study aimed to obtain comprehensive data on the current state of cytopathology education for residents and evaluate education outcomes.
Methods
An online survey was conducted in December 2020 for the board-certified pathologists and training residents registered as members of the Korean Society for Cytopathology. The questionnaire comprised questions that investigated the current status of cytopathology at each training institution, the degree of satisfaction with the work and education related to cytopathology, outcomes of cytopathology training, and educational accomplishments.
Results
Of the participants surveyed, 12.3% (132/1,075) completed the questionnaire, and 36.8% (32/87) of cytopathology residents participated. The mean overall satisfaction with cytopathology education was 3.1 points (on a 1- to 5-point scale, 5: very satisfied). The most frequent suggestion among the free description format responses was to expand educational opportunities, such as online education opportunities, outside of the individual institutions.
Conclusions
Our results showed that cytopathology training in Korea needs further improvement. We expect that this study will inform systematic training of competent medical personnel armed with broad cytopathology knowledge and strong problem-solving abilities.
A standardized pathology report for gastric cancer: 2nd edition
Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi, Hee Kyung Chang, Soomin Ahn, Mee Soo Chang, Song-Hee Han, Yoonjin Kwak, An Na Seo, Sung Hak Lee, Mee-Yon Cho
J Pathol Transl Med. 2023;57(1):1-27.   Published online January 15, 2023
DOI: https://doi.org/10.4132/jptm.2022.12.23
  • 1,063 View
  • 227 Download
AbstractAbstract PDFSupplementary Material
The first edition of ‘A Standardized Pathology Report for Gastric Cancer’ was initiated by the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists and published 17 years ago. Since then, significant advances have been made in the pathologic diagnosis, molecular genetics, and management of gastric cancer (GC). To reflect those changes, a committee for publishing a second edition of the report was formed within the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. This second edition consists of two parts: standard data elements and conditional data elements. The standard data elements contain the basic pathologic findings and items necessary to predict the prognosis of GC patients, and they are adequate for routine surgical pathology service. Other diagnostic and prognostic factors relevant to adjuvant therapy, including molecular biomarkers, are classified as conditional data elements to allow each pathologist to selectively choose items appropriate to the environment in their institution. We trust that the standardized pathology report will be helpful for GC diagnosis and facilitate large-scale multidisciplinary collaborative studies.
Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea
Sunhee Chang, Yoon-La Choi, Hyo Sup Shim, Geon Kook Lee, Seung Yeon Ha
J Pathol Transl Med. 2022;56(6):334-341.   Published online October 27, 2022
DOI: https://doi.org/10.4132/jptm.2022.08.22
  • 1,134 View
  • 74 Download
AbstractAbstract PDF
Background
Next-generation sequencing (NGS) is an approved test to select patients for BRAF V600E targeted therapy in Korea. However, the high cost, long turnaround times, and the need for sophisticated equipment and skilled personnel limit the use of NGS in daily practice. Immunohistochemistry (IHC) is a rapid and relatively inexpensive assay available in most laboratories. Therefore, in this study, we evaluate the usefulness of BRAF VE1 IHC in terms of predictive value and interobserver agreement in non–small cell lung cancers (NSCLCs).
Methods
A total of 30 cases with known BRAF mutation status were selected, including 20 cases of lung adenocarcinomas, six cases of colorectal adenocarcinomas, and four cases of papillary thyroid carcinomas. IHC for BRAF V600E was carried out using the VE1 antibody. Fifteen pathologists independently scored both the staining intensity and the percentage of tumor cell staining on whole slide images.
Results
In the lung adenocarcinoma subset, interobserver agreement for the percentage of tumor cell staining and staining intensity was good (percentage of tumor cell staining, intraclass correlation coefficient = 0.869; staining intensity, kappa = 0.849). The interobserver agreement for the interpretation using the cutoff of 40% was almost perfect in the entire study group and the lung adenocarcinoma subset (kappa = 0.815). Sensitivity, specificity, positive predictive value, and negative predictive value of BRAF VE1 IHC were 80.0%, 90.0%, 88.9%, and 81.8%, respectively.
Conclusions
BRAF VE1 IHC could be a screening test for the detection of BRAF V600E mutation in NSCLC. However, further studies are needed to optimize the protocol and to establish and validate interpretation criteria for BRAF VE1 IHC.
Current status of cytopathology practice in Korea: impact of the coronavirus pandemic on cytopathology practice
Soon Auck Hong, Haeyoen Jung, Sung Sun Kim, Min-Sun Jin, Jung-Soo Pyo, Ji Yun Jeong, Younghee Choi, Gyungyub Gong, Yosep Chong
J Pathol Transl Med. 2022;56(6):361-369.   Published online October 27, 2022
DOI: https://doi.org/10.4132/jptm.2022.09.21
  • 1,078 View
  • 56 Download
AbstractAbstract PDFSupplementary Material
Background
The Continuous Quality Improvement program for cytopathology in 2020 was completed during the coronavirus pandemic. In this study, we report the result of the quality improvement program.
Methods
Data related to cytopathology practice from each institute were collected and processed at the web-based portal. The proficiency test was conducted using glass slides and whole-slide images (WSIs). Evaluation of the adequacy of gynecology (GYN) slides from each institution and submission of case glass slides and WSIs for the next quality improvement program were performed.
Results
A total of 214 institutions participated in the annual cytopathology survey in 2020. The number of entire cytopathology specimens was 8,220,650, a reduction of 19.0% from the 10,111,755 specimens evaluated in 2019. Notably, the number of respiratory cytopathology specimens, including sputum and bronchial washing/ brushing significantly decreased by 86.9% from 2019, which could be attributed to the global pandemic of coronavirus disease. The ratio of cases with atypical squamous cells to squamous intraepithelial lesions was 4.10. All participating institutions passed the proficiency test and the evaluation of adequacy of GYN slides.
Conclusions
Through the Continuous Quality Improvement program, the effect of coronavirus disease 2019 pandemic, manifesting with a reduction in the number of cytologic examinations, especially in respiratory-related specimen has been identified. The Continuous Quality Improvement Program of the Korean Society for Cytopathology can serve as the gold standard to evaluate the current status of cytopathology practice in Korea.
Standardization of the pathologic diagnosis of appendiceal mucinous neoplasms
Dong-Wook Kang, Baek-hui Kim, Joon Mee Kim, Jihun Kim, Hee Jin Chang, Mee Soo Chang, Jin-Hee Sohn, Mee-Yon Cho, So-Young Jin, Hee Kyung Chang, Hye Seung Han, Jung Yeon Kim, Hee Sung Kim, Do Youn Park, Ha Young Park, So Jeong Lee, Wonae Lee, Hye Seung Lee, Yoo Na Kang, Younghee Choi
J Pathol Transl Med. 2021;55(4):247-264.   Published online July 8, 2021
DOI: https://doi.org/10.4132/jptm.2021.05.28
  • 6,704 View
  • 534 Download
  • 2 Citations
AbstractAbstract PDFSupplementary Material
Although the understanding of appendiceal mucinous neoplasms (AMNs) and their relationship with disseminated peritoneal mucinous disease have advanced, the diagnosis, classification, and treatment of AMNs are still confusing for pathologists and clinicians. The Gastrointestinal Pathology Study Group of the Korean Society of Pathologists (GPSG-KSP) proposed a multicenter study and held a workshop for the “Standardization of the Pathologic Diagnosis of the Appendiceal Mucinous Neoplasm” to overcome the controversy and potential conflicts. The present article is focused on the diagnostic criteria, terminologies, tumor grading, pathologic staging, biologic behavior, treatment, and prognosis of AMNs and disseminated peritoneal mucinous disease. In addition, GPSG-KSP proposes a checklist of standard data elements of appendiceal epithelial neoplasms to standardize pathologic diagnosis. We hope the present article will provide pathologists with updated knowledge on how to handle and diagnose AMNs and disseminated peritoneal mucinous disease.

Citations

Citations to this article as recorded by  
  • Delivery of an Incidental Appendiceal Mucinous Neoplasm
    Madison Bowles, Jessica Y Ng, Hajir Nabi
    Cureus.2022;[Epub]     CrossRef
  • Unearthing novel fusions as therapeutic targets in solid tumors using targeted RNA sequencing
    Sungbin An, Hyun Hee Koh, Eun Sol Chang, Juyoung Choi, Ji-Young Song, Mi-Sook Lee, Yoon-La Choi
    Frontiers in Oncology.2022;[Epub]     CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
J Pathol Transl Med. 2021;55(3):181-191.   Published online May 11, 2021
DOI: https://doi.org/10.4132/jptm.2021.03.23
  • 3,700 View
  • 234 Download
  • 7 Citations
AbstractAbstract PDF
Molecular biomarker testing is the standard of care for non–small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.

Citations

Citations to this article as recorded by  
  • FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC
    Anke Behnke, Anne Cayre, Giovanna De Maglio, Giuseppe Giannini, Lionel Habran, Marina Tarsitano, Massimiliano Chetta, David Cappellen, Alexandra Lespagnol, Cecile Le Naoures, Gabriella Massazza, Annarita Destro, Irina Bonzheim, Achim Rau, Achim Battmann,
    Pathology and Oncology Research.2023;[Epub]     CrossRef
  • Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics
    Hyun Hee Koh, Eunhyang Park, Hyun-Soo Kim
    Diagnostics.2022; 12(2): 326.     CrossRef
  • Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics
    Yurimi Lee, Kiyong Na, Ha Young Woo, Hyun-Soo Kim
    Diagnostics.2022; 12(5): 1102.     CrossRef
  • Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
    Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(5): 249.     CrossRef
  • Biomarker testing of cytology specimens in personalized medicine for lung cancer patients
    Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(6): 326.     CrossRef
  • Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea
    Sunhee Chang, Yoon-La Choi, Hyo Sup Shim, Geon Kook Lee, Seung Yeon Ha
    Journal of Pathology and Translational Medicine.2022; 56(6): 334.     CrossRef
  • Lung Cancer in Korea
    Sehhoon Park, Chang-Min Choi, Seung-Sik Hwang, Yoon-La Choi, Hyae Young Kim, Young-Chul Kim, Young Tae Kim, Ho Yun Lee, Si Yeol Song, Myung-Ju Ahn
    Journal of Thoracic Oncology.2021; 16(12): 1988.     CrossRef
Recommendations for pathologic practice using digital pathology: consensus report of the Korean Society of Pathologists
Yosep Chong, Dae Cheol Kim, Chan Kwon Jung, Dong-chul Kim, Sang Yong Song, Hee Jae Joo, Sang-Yeop Yi
J Pathol Transl Med. 2020;54(6):437-452.   Published online October 8, 2020
DOI: https://doi.org/10.4132/jptm.2020.08.27
  • 5,363 View
  • 248 Download
  • 8 Citations
AbstractAbstract PDFSupplementary Material
Digital pathology (DP) using whole slide imaging (WSI) is becoming a fundamental issue in pathology with recent advances and the rapid development of associated technologies. However, the available evidence on its diagnostic uses and practical advice for pathologists on implementing DP remains insufficient, particularly in light of the exponential growth of this industry. To inform DP implementation in Korea, we developed relevant and timely recommendations. We first performed a literature review of DP guidelines, recommendations, and position papers from major countries, as well as a review of relevant studies validating WSI. Based on that information, we prepared a draft. After several revisions, we released this draft to the public and the members of the Korean Society of Pathologists through our homepage and held an open forum for interested parties. Through that process, this final manuscript has been prepared. This recommendation contains an overview describing the background, objectives, scope of application, and basic terminology; guidelines and considerations for the hardware and software used in DP systems and the validation required for DP implementation; conclusions; and references and appendices, including literature on DP from major countries and WSI validation studies.

Citations

Citations to this article as recorded by  
  • Understanding the ethical and legal considerations of Digital Pathology
    Cheryl Coulter, Francis McKay, Nina Hallowell, Lisa Browning, Richard Colling, Philip Macklin, Tom Sorell, Muhammad Aslam, Gareth Bryson, Darren Treanor, Clare Verrill
    The Journal of Pathology: Clinical Research.2022; 8(2): 101.     CrossRef
  • Current Trend of Artificial Intelligence Patents in Digital Pathology: A Systematic Evaluation of the Patent Landscape
    Muhammad Joan Ailia, Nishant Thakur, Jamshid Abdul-Ghafar, Chan Kwon Jung, Kwangil Yim, Yosep Chong
    Cancers.2022; 14(10): 2400.     CrossRef
  • Recent Applications of Artificial Intelligence from Histopathologic Image-Based Prediction of Microsatellite Instability in Solid Cancers: A Systematic Review
    Mohammad Rizwan Alam, Jamshid Abdul-Ghafar, Kwangil Yim, Nishant Thakur, Sung Hak Lee, Hyun-Jong Jang, Chan Kwon Jung, Yosep Chong
    Cancers.2022; 14(11): 2590.     CrossRef
  • Automated Hybrid Model for Detecting Perineural Invasion in the Histology of Colorectal Cancer
    Jiyoon Jung, Eunsu Kim, Hyeseong Lee, Sung Hak Lee, Sangjeong Ahn
    Applied Sciences.2022; 12(18): 9159.     CrossRef
  • Development of quality assurance program for digital pathology by the Korean Society of Pathologists
    Yosep Chong, Jeong Mo Bae, Dong Wook Kang, Gwangil Kim, Hye Seung Han
    Journal of Pathology and Translational Medicine.2022; 56(6): 370.     CrossRef
  • Improving quality control in the routine practice for histopathological interpretation of gastrointestinal endoscopic biopsies using artificial intelligence
    Young Sin Ko, Yoo Mi Choi, Mujin Kim, Youngjin Park, Murtaza Ashraf, Willmer Rafell Quiñones Robles, Min-Ju Kim, Jiwook Jang, Seokju Yun, Yuri Hwang, Hani Jang, Mun Yong Yi, Anwar P.P. Abdul Majeed
    PLOS ONE.2022; 17(12): e0278542.     CrossRef
  • Diagnostic Assessment of Deep Learning Algorithms for Frozen Tissue Section Analysis in Women with Breast Cancer
    Young-Gon Kim, In Hye Song, Seung Yeon Cho, Sungchul Kim, Milim Kim, Soomin Ahn, Hyunna Lee, Dong Hyun Yang, Namkug Kim, Sungwan Kim, Taewoo Kim, Daeyoung Kim, Jonghyeon Choi, Ki-Sun Lee, Minuk Ma, Minki Jo, So Yeon Park, Gyungyub Gong
    Cancer Research and Treatment.2022;[Epub]     CrossRef
  • What is Essential is (No More) Invisible to the Eyes: The Introduction of BlocDoc in the Digital Pathology Workflow
    Vincenzo L’Imperio, Fabio Gibilisco, Filippo Fraggetta
    Journal of Pathology Informatics.2021; 12(1): 32.     CrossRef
Current status of cytopathology practices in Korea: annual report on the Continuous Quality Improvement program of the Korean Society for Cytopathology for 2018
Yosep Chong, Haeyoen Jung, Jung-Soo Pyo, Soon Won Hong, Hoon Kyu Oh
J Pathol Transl Med. 2020;54(4):318-331.   Published online April 15, 2020
DOI: https://doi.org/10.4132/jptm.2020.02.26
  • 3,769 View
  • 88 Download
  • 3 Citations
AbstractAbstract PDFSupplementary Material
Background
The Korean Society for Cytopathology has conducted the Continuous Quality Improvement program for cytopathology laboratories in Korea since 1995. In 2018 as part of the program, an annual survey of cytologic data was administered to determine the current status of cytopathology practices in Korea. Methods: A questionnaire was administered to 211 cytopathology laboratories. Individual laboratories submitted their annual statistics regarding cytopathology practices, diagnoses of gynecologic samples, inadequacy rates, and gynecologic cytology-histology correlation review (CHCR) data for 2018. In addition, proficiency tests and sample adequacy assessments were conducted using five consequent gynecologic slides. Results: Over 10 million cytologic exams were performed in 2018, and this number has almost tripled since this survey was first conducted in 2004 (compounded annual growth rate of 7.2%). The number of non-gynecologic samples has increased gradually over time and comprised 24% of all exams. The overall unsatisfactory rate was 0.14%. The ratio of the cases with atypical squamous cells to squamous intraepithelial lesions accounted for up to 4.24. The major discrepancy rate of the CHCR in gynecologic samples was 0.52%. In the proficiency test, the major discrepancy rate was approximately 1%. In the sample adequacy assessment, a discrepancy was observed in 0.1% of cases. Conclusions: This study represents the current status of cytopathology practices in Korea, illustrating the importance of the Continuous Quality Improvement program for increasing the accuracy and credibility of cytopathologic exams as well as developing national cancer exam guidelines and government projects on the prevention and treatment of cancer.

Citations

Citations to this article as recorded by  
  • Recent Application of Artificial Intelligence in Non-Gynecological Cancer Cytopathology: A Systematic Review
    Nishant Thakur, Mohammad Rizwan Alam, Jamshid Abdul-Ghafar, Yosep Chong
    Cancers.2022; 14(14): 3529.     CrossRef
  • Re-Increasing Trends in Thyroid Cancer Incidence after a Short Period of Decrease in Korea: Reigniting the Debate on Ultrasound Screening
    Chan Kwon Jung, Ja Seong Bae, Young Joo Park
    Endocrinology and Metabolism.2022; 37(5): 816.     CrossRef
  • Current status of cytopathology practice in Korea: impact of the coronavirus pandemic on cytopathology practice
    Soon Auck Hong, Haeyoen Jung, Sung Sun Kim, Min-Sun Jin, Jung-Soo Pyo, Ji Yun Jeong, Younghee Choi, Gyungyub Gong, Yosep Chong
    Journal of Pathology and Translational Medicine.2022; 56(6): 361.     CrossRef
Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea
Yoon Jin Cha, Se Hoon Kim, Na Rae Kim
J Pathol Transl Med. 2020;54(2):165-170.   Published online February 20, 2020
DOI: https://doi.org/10.4132/jptm.2020.02.04
  • 5,217 View
  • 202 Download
  • 1 Citations
AbstractAbstract PDFSupplementary Material
Background
The revised 4th 2016 World Health Organization (WHO) classification of tumors of the central nervous system (CNS) classification has adopted integrated diagnosis encompassing the histology and molecular features of CNS tumors. We aimed to investigate the immunohistochemistry, molecular testing, and testing methods for diagnosis of CNS tumors in pathological labs of tertiary centers in Korea, and evaluate the adequacy of tests for proper diagnosis in daily practice.
Methods
A survey, composed of eight questions concerning molecular testing for diagnosis of CNS tumors, was sent to 10 neuropathologists working in tertiary centers in Korea.
Results
For diagnosis of astrocytic and oligodendroglial tumors, all 10 centers performed isocitrate dehydrogenase mutations testing and 1p/19q loss of heterozygosity. For glioneuronal tumors, immunohistochemistry (IHC) assays for synaptophysin (n = 9), CD34 (n = 7), BRAF(VE1) (n = 5) were used. For embryonal tumors, particularly in medulloblastoma, four respondents used IHC panel (growth factor receptor bound protein 2-associated protein 1, filamin A, and yes-associated protein 1) for molecular subclassification. Regarding meningioma, all respondents performed Ki-67 IHC and five performed telomerase reverse transcriptase promoter mutation.
Conclusions
Most tertiary centers made proper diagnosis in line with 2016 WHO classification. As classification of CNS tumors has evolved to be more complex and more ancillary tests are required, these should be performed considering the effect of necessity and justification.

Citations

Citations to this article as recorded by  
  • Exploring the role of epidermal growth factor receptor variant III in meningeal tumors
    Rashmi Rana, Vaishnavi Rathi, Kirti Chauhan, Kriti Jain, Satnam Singh Chhabra, Rajesh Acharya, Samir Kumar Kalra, Anshul Gupta, Sunila Jain, Nirmal Kumar Ganguly, Dharmendra Kumar Yadav, Timir Tripathi
    PLOS ONE.2021; 16(9): e0255133.     CrossRef
Standardized Pathology Report for Colorectal Cancer, 2nd Edition
Baek-hui Kim, Joon Mee Kim, Gyeong Hoon Kang, Hee Jin Chang, Dong Wook Kang, Jung Ho Kim, Jeong Mo Bae, An Na Seo, Ho Sung Park, Yun Kyung Kang, Kyung-Hwa Lee, Mee Yon Cho, In-Gu Do, Hye Seung Lee, Hee Kyung Chang, Do Youn Park, Hyo Jeong Kang, Jin Hee Sohn, Mee Soo Chang, Eun Sun Jung, So-Young Jin, Eunsil Yu, Hye Seung Han, Youn Wha Kim
J Pathol Transl Med. 2020;54(1):1-19.   Published online November 13, 2019
DOI: https://doi.org/10.4132/jptm.2019.09.28
  • 15,165 View
  • 957 Download
  • 26 Citations
AbstractAbstract PDFSupplementary Material
The first edition of the ‘Standardized Pathology Report for Colorectal Cancer,’ which was developed by the Gastrointestinal Pathology Study Group (GIP) of the Korean Society of Pathologists, was published 13 years ago. Meanwhile, there have been many changes in the pathologic diagnosis of colorectal cancer (CRC), pathologic findings included in the pathology report, and immunohistochemical and molecular pathology required for the diagnosis and treatment of colorectal cancer. In order to reflect these changes, we (GIP) decided to make the second edition of the report. The purpose of this standardized pathology report is to provide a practical protocol for Korean pathologists, which could help diagnose and treat CRC patients. This report consists of “standard data elements” and “conditional data elements.” Basic pathologic findings and parts necessary for prognostication of CRC patients are classified as “standard data elements,” while other prognostic factors and factors related to adjuvant therapy are classified as “conditional data elements” so that each institution could select the contents according to the characteristics of the institution. The Korean version is also provided separately so that Korean pathologists can easily understand and use this report. We hope that this report will be helpful in the daily practice of CRC diagnosis.

Citations

Citations to this article as recorded by  
  • Pathologic Implications of Magnetic Resonance Imaging-detected Extramural Venous Invasion of Rectal Cancer
    Hyun Gu Lee, Chan Wook Kim, Jong Keon Jang, Seong Ho Park, Young Il Kim, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Clinical Colorectal Cancer.2023; 22(1): 129.     CrossRef
  • A standardized pathology report for gastric cancer: 2nd edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Pathology and Translational Medicine.2023; 57(1): 1.     CrossRef
  • IGFL2-AS1, a Long Non-Coding RNA, Is Associated with Radioresistance in Colorectal Cancer
    Jeeyong Lee, Da Yeon Kim, Younjoo Kim, Ui Sup Shin, Kwang Seok Kim, Eun Ju Kim
    International Journal of Molecular Sciences.2023; 24(2): 978.     CrossRef
  • A Standardized Pathology Report for Gastric Cancer: 2nd Edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Gastric Cancer.2023; 23(1): 107.     CrossRef
  • Incremental Detection Rate of Dysplasia and Sessile Serrated Polyps/Adenomas Using Narrow-Band Imaging and Dye Spray Chromoendoscopy in Addition to High-Definition Endoscopy in Patients with Long-Standing Extensive Ulcerative Colitis: Segmental Tandem End
    Ji Eun Kim, Chang Wan Choi, Sung Noh Hong, Joo Hye Song, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
    Diagnostics.2023; 13(3): 516.     CrossRef
  • Prognostic Impact of Extramural Lymphatic, Vascular, and Perineural Invasion in Stage II Colon Cancer: A Comparison With Intramural Invasion
    Sang Sik Cho, Ji Won Park, Gyeong Hoon Kang, Jung Ho Kim, Jeong Mo Bae, Sae-Won Han, Tae-You Kim, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park
    Diseases of the Colon & Rectum.2023; 66(3): 366.     CrossRef
  • Polo-like kinase 4 as a potential predictive biomarker of chemoradioresistance in locally advanced rectal cancer
    Hyunseung Oh, Soon Gu Kim, Sung Uk Bae, Sang Jun Byun, Shin Kim, Jae-Ho Lee, Ilseon Hwang, Sun Young Kwon, Hye Won Lee
    Journal of Pathology and Translational Medicine.2022; 56(1): 40.     CrossRef
  • A Prediction Model for Tumor Recurrence in Stage II–III Colorectal Cancer Patients: From a Machine Learning Model to Genomic Profiling
    Po-Chuan Chen, Yu-Min Yeh, Bo-Wen Lin, Ren-Hao Chan, Pei-Fang Su, Yi-Chia Liu, Chung-Ta Lee, Shang-Hung Chen, Peng-Chan Lin
    Biomedicines.2022; 10(2): 340.     CrossRef
  • Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1
    Zhengyang Yang, Xiao Zhang, Jie Zhang, Jiale Gao, Zhigang Bai, Wei Deng, Guangyong Chen, Yongbo An, Yishan Liu, Qi Wei, Jiagang Han, Ang Li, Gang Liu, Yi Sun, Dalu Kong, Hongwei Yao, Zhongtao Zhang
    BMC Cancer.2022;[Epub]     CrossRef
  • Potential of DEK proto‑oncogene as a prognostic biomarker for colorectal cancer: An evidence‑based review
    Muhammad Habiburrahman, Muhammad Wardoyo, Stefanus Sutopo, Nur Rahadiani
    Molecular and Clinical Oncology.2022;[Epub]     CrossRef
  • Reproducibility and Feasibility of Classification and National Guidelines for Histological Diagnosis of Canine Mammary Gland Tumours: A Multi-Institutional Ring Study
    Serenella Papparella, Maria Ines Crescio, Valeria Baldassarre, Barbara Brunetti, Giovanni P. Burrai, Cristiano Cocumelli, Valeria Grieco, Selina Iussich, Lorella Maniscalco, Francesca Mariotti, Francesca Millanta, Orlando Paciello, Roberta Rasotto, Mariar
    Veterinary Sciences.2022; 9(7): 357.     CrossRef
  • Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer
    Jeong-ki Kim, Ye-Young Rhee, Jeong Mo Bae, Jung Ho Kim, Seong-Joon Koh, Hyun Jung Lee, Jong Pil Im, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park, Ji Won Park, Gyeong Hoon Kang
    BMC Cancer.2022;[Epub]     CrossRef
  • Automated Hybrid Model for Detecting Perineural Invasion in the Histology of Colorectal Cancer
    Jiyoon Jung, Eunsu Kim, Hyeseong Lee, Sung Hak Lee, Sangjeong Ahn
    Applied Sciences.2022; 12(18): 9159.     CrossRef
  • Clinical Implication of Perineural and Lymphovascular Invasion in Rectal Cancer Patients Who Underwent Surgery After Preoperative Chemoradiotherapy
    Young Il Kim, Chan Wook Kim, Jong Hoon Kim, Jihun Kim, Jun-Soo Ro, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Diseases of the Colon & Rectum.2022; 65(11): 1325.     CrossRef
  • Molecular Pathology of Gastric Cancer
    Moonsik Kim, An Na Seo
    Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
  • Selective approach to arterial ligation in radical sigmoid colon cancer surgery with D3 lymph node dissection: A multicenter comparative study
    Sergey Efetov, Albina Zubayraeva, Cüneyt Kayaalp, Alisa Minenkova, Yusuf Bağ, Aftandil Alekberzade, Petr Tsarkov
    Turkish Journal of Surgery.2022; 38(4): 382.     CrossRef
  • Evaluation of lncRNA FOXD2-AS1 Expression as a Diagnostic Biomarker in Colorectal Cancer
    Hooman Shalmashi, Sahar Safaei, Dariush Shanehbandi, Milad Asadi, Soghra Bornehdeli, Abdolreza Mehdi Navaz
    Reports of Biochemistry and Molecular Biology.2022; 11(3): 471.     CrossRef
  • Improvement in the Assessment of Response to Preoperative Chemoradiotherapy for Rectal Cancer Using Magnetic Resonance Imaging and a Multigene Biomarker
    Eunhae Cho, Sung Woo Jung, In Ja Park, Jong Keon Jang, Seong Ho Park, Seung-Mo Hong, Jong Lyul Lee, Chan Wook Kim, Yong Sik Yoon, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Cancers.2021; 13(14): 3480.     CrossRef
  • Addition of V-Stage to Conventional TNM Staging to Create the TNVM Staging System for Accurate Prediction of Prognosis in Colon Cancer: A Multi-Institutional Retrospective Cohort Study
    Jung Hoon Bae, Ji Hoon Kim, Jaeim Lee, Bong-Hyeon Kye, Sang Chul Lee, In Kyu Lee, Won Kyung Kang, Hyeon-Min Cho, Yoon Suk Lee
    Biomedicines.2021; 9(8): 888.     CrossRef
  • Gene Expression Profiles Associated with Radio-Responsiveness in Locally Advanced Rectal Cancer
    Jeeyong Lee, Junhye Kwon, DaYeon Kim, Misun Park, KwangSeok Kim, InHwa Bae, Hyunkyung Kim, JoonSeog Kong, Younjoo Kim, UiSup Shin, EunJu Kim
    Biology.2021; 10(6): 500.     CrossRef
  • A Patient-Derived Organoid-Based Radiosensitivity Model for the Prediction of Radiation Responses in Patients with Rectal Cancer
    Misun Park, Junhye Kwon, Joonseog Kong, Sun Mi Moon, Sangsik Cho, Ki Young Yang, Won Il Jang, Mi Sook Kim, Younjoo Kim, Ui Sup Shin
    Cancers.2021; 13(15): 3760.     CrossRef
  • Comparison between Local Excision and Radical Resection for the Treatment of Rectal Cancer in ypT0-1 Patients: An Analysis of the Clinicopathological Factors and Survival Rates
    Soo Young Oh, In Ja Park, Young IL Kim, Jong-Lyul Lee, Chan Wook Kim, Yong Sik Yoon, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Cancers.2021; 13(19): 4823.     CrossRef
  • Comparison of Vascular Invasion With Lymph Node Metastasis as a Prognostic Factor in Stage I-III Colon Cancer: An Observational Cohort Study
    Jung Hoon Bae, Ji Hoon Kim, Bong-Hyeon Kye, Abdullah Al-Sawat, Chul Seung Lee, Seung-Rim Han, In Kyu Lee, Sung Hak Lee, Yoon Suk Lee
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • Clinicopathological significance of Ki67 expression in colorectal cancer
    Jing Li, Zhi-ye Liu, Hai-bo Yu, Qing Xue, Wen-jie He, Hai-tao Yu
    Medicine.2020; 99(20): e20136.     CrossRef
  • Lateral lymph node and its association with distant recurrence in rectal cancer: A clue of systemic disease
    Young Il Kim, Jong Keon Jang, In Ja Park, Seong Ho Park, Jong Beom Kim, Jin-Hong Park, Tae Won Kim, Jun-Soo Ro, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Surgical Oncology.2020; 35: 174.     CrossRef
  • Transformation of Pathology Reports Into the Common Data Model With Oncology Module: Use Case for Colon Cancer
    Borim Ryu, Eunsil Yoon, Seok Kim, Sejoon Lee, Hyunyoung Baek, Soyoung Yi, Hee Young Na, Ji-Won Kim, Rong-Min Baek, Hee Hwang, Sooyoung Yoo
    Journal of Medical Internet Research.2020; 22(12): e18526.     CrossRef
2019 Practice guidelines for thyroid core needle biopsy: a report of the Clinical Practice Guidelines Development Committee of the Korean Thyroid Association
Chan Kwon Jung, Jung Hwan Baek, Dong Gyu Na, Young Lyun Oh, Ka Hee Yi, Ho-Cheol Kang
J Pathol Transl Med. 2020;54(1):64-86.   Published online January 15, 2020
DOI: https://doi.org/10.4132/jptm.2019.12.04
  • 16,624 View
  • 728 Download
  • 20 Citations
AbstractAbstract PDF
Ultrasound-guided core needle biopsy (CNB) has been increasingly used for the pre-operative diagnosis of thyroid nodules. Since the Korean Society of the Thyroid Radiology published the ‘Consensus Statement and Recommendations for Thyroid CNB’ in 2017 and the Korean Endocrine Pathology Thyroid CNB Study Group published ‘Pathology Reporting of Thyroid Core Needle Biopsy’ in 2015, advances have occurred rapidly not only in the management guidelines for thyroid nodules but also in the diagnostic terminology and classification schemes. The Clinical Practice Guidelines Development Committee of the Korean Thyroid Association (KTA) reviewed publications on thyroid CNB from 1995 to September 2019 and updated the recommendations and statements for the diagnosis and management of thyroid nodules using CNB. Recommendations for the resolution of clinical controversies regarding the use of CNB were based on expert opinion. These practical guidelines include recommendations and statements regarding indications for CNB, patient preparation, CNB technique, biopsy-related complications, biopsy specimen preparation and processing, and pathology interpretation and reporting of thyroid CNB.

Citations

Citations to this article as recorded by  
  • Comparison of Core Needle Biopsy and Repeat Fine-Needle Aspiration in Avoiding Diagnostic Surgery for Thyroid Nodules Initially Diagnosed as Atypia/Follicular Lesion of Undetermined Significance
    Leehi Joo, Dong Gyu Na, Ji-hoon Kim, Hyobin Seo
    Korean Journal of Radiology.2022; 23(2): 280.     CrossRef
  • Diagnostic efficacy, performance and safety of side-cut core needle biopsy for thyroid nodules: comparison of automated and semi-automated biopsy needles
    Ji Yeon Park, Seong Yoon Yi, Soo Heui Baek, Yu Hyun Lee, Heon-Ju Kwon, Hee Jin Park
    Endocrine.2022; 76(2): 341.     CrossRef
  • Thyroid Cancer Diagnostics Related to Occupational and Environmental Risk Factors: An Integrated Risk Assessment Approach
    Gabriela Maria Berinde, Andreea Iulia Socaciu, Mihai Adrian Socaciu, Andreea Cozma, Armand Gabriel Rajnoveanu, Gabriel Emil Petre, Doina Piciu
    Diagnostics.2022; 12(2): 318.     CrossRef
  • Approach to Bethesda system category III thyroid nodules according to US-risk stratification
    Jieun Kim, Jung Hee Shin, Young Lyun Oh, Soo Yeon Hahn, Ko Woon Park
    Endocrine Journal.2022; 69(1): 67.     CrossRef
  • Clinicopathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management
    Marie Nguyen, George He, Alfred King-Yin Lam
    International Journal of Molecular Sciences.2022; 23(6): 3242.     CrossRef
  • Diagnostic Performance of Thyroid Core Needle Biopsy Using the Revised Reporting System: Comparison with Fine Needle Aspiration Cytology
    Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, So Lyung Jung, Chan Kwon Jung
    Endocrinology and Metabolism.2022; 37(1): 159.     CrossRef
  • Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses
    Antonio Matrone, Luigi De Napoli, Liborio Torregrossa, Aleksandr Aghababyan, Piermarco Papini, Carlo Enrico Ambrosini, Rosa Cervelli, Clara Ugolini, Fulvio Basolo, Eleonora Molinaro, Rossella Elisei, Gabriele Materazzi
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Primary thyroid leiomyosarcoma with transvenous extension to the right atrium: a case report
    Juraj Dubrava, Peter Martanovic, Marina Pavlovicova, Pavel Babal, Akhil Narang, Maria Mattioli, Nidhish Tiwari, Zhiyu Liu, Mariame Chakir
    European Heart Journal - Case Reports.2022;[Epub]     CrossRef
  • Radiofrequency ablation for management of thyroid nodules in quarantine zone of COVID-19 pandemic setting in Indonesia
    Kristanto Yuli Yarso, Sumadi Lukman Anwar
    Annals of Medicine and Surgery.2022; 81: 104132.     CrossRef
  • A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
    Faridul Haq, Andrey Bychkov, Chan Kwon Jung
    Endocrine Pathology.2022; 33(4): 472.     CrossRef
  • Risk of thyroid cancer in a lung cancer screening population of the national lung screening trial according to the presence of incidental thyroid nodules detected on low-dose chest CT
    Hyobin Seo, Kwang Nam Jin, Ji Sang Park, Koung Mi Kang, Eun Kyung Lee, Ji Ye Lee, Roh-Eul Yoo, Young Joo Park, Ji-hoon Kim
    Ultrasonography.2022;[Epub]     CrossRef
  • Diagnostic performance of core needle biopsy as a first‐line diagnostic tool for thyroid nodules according to ultrasound patterns: Comparison with fine needle aspiration using propensity score matching analysis
    Hye Shin Ahn, Inyoung Youn, Dong Gyu Na, Soo Jin Kim, Mi Yeon Lee
    Clinical Endocrinology.2021; 94(3): 494.     CrossRef
  • Hydrodissection: A Novel Approach for Safe Core Needle Biopsy of Small High-Risk Subcapsular Thyroid Nodules
    Hojat Ebrahiminik, Hossein Chegeni, Javad Jalili, Rambod Salouti, Hadi Rokni, Afshin Mohammadi, Ali Mosaddegh Khah, Seyed Mohammad Tavangar, Zahra Ebrahiminik
    CardioVascular and Interventional Radiology.2021; 44(10): 1651.     CrossRef
  • Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules
    Yan Xiong, Xin Li, Li Liang, Dong Li, Limin Yan, Xueying Li, Jiting Di, Ting Li
    Virchows Archiv.2021; 479(5): 961.     CrossRef
  • VE1 immunohistochemistry is an adjunct tool for detection of BRAF V600E mutation: Validation in thyroid cancer patients
    Faiza A. Rashid, Sobia Tabassum, Mosin S. Khan, Hifzur R. Ansari, Muhammad Asif, Ahmareen K. Sheikh, Syed Aga
    Journal of Clinical Laboratory Analysis.2021;[Epub]     CrossRef
  • The Diagnostic Value of the American College of Radiology Thyroid Imaging Reporting and Data System Classification and Shear-Wave Elastography for the Differentiation of Thyroid Nodules
    Gül Bora Makal, Aydın Aslan
    Ultrasound in Medicine & Biology.2021; 47(5): 1227.     CrossRef
  • Comparison of the diagnostic performance of the modified Korean Thyroid Imaging Reporting and Data System for thyroid malignancy with three international guidelines
    Eun Ju Ha, Jung Hee Shin, Dong Gyu Na, So Lyung Jung, Young Hen Lee, Wooyul Paik, Min Ji Hong, Yeo Koon Kim, Chang Yoon Lee
    Ultrasonography.2021; 40(4): 594.     CrossRef
  • VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer
    Sonam Choden, Somboon Keelawat, Chan Kwon Jung, Andrey Bychkov
    Cancers.2020; 12(3): 596.     CrossRef
  • The 2019 core-needle biopsy practice guidelines
    So Yeong Jeong, Jung Hwan Baek
    Ultrasonography.2020; 39(3): 311.     CrossRef
  • Re: The 2019 core-needle biopsy practice guidelines
    Ji-hoon Kim
    Ultrasonography.2020; 39(3): 313.     CrossRef
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
Sunhee Chang, Hyung Kyu Park, Yoon-La Choi, Se Jin Jang
J Pathol Transl Med. 2019;53(6):347-353.   Published online October 28, 2019
DOI: https://doi.org/10.4132/jptm.2019.09.29
  • 4,727 View
  • 184 Download
  • 19 Citations
AbstractAbstract PDF
Background
Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples.
Methods
Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS: <1%, 1%–49%, and ≥50%.
Results
The intraclass correlation coefficient for TPS was 0.902±0.058. Weighted κ coefficient for 3-step assessment was 0.748±0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type.
Conclusions
Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti–PD-1 therapy in NSCLC.

Citations

Citations to this article as recorded by  
  • Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer
    Jianghua Wu, Changling Liu, Xiaoqing Liu, Wei Sun, Linfeng Li, Nannan Gao, Yajun Zhang, Xin Yang, Junjie Zhang, Haiyue Wang, Xinying Liu, Xiaozheng Huang, Yanhui Zhang, Runfen Cheng, Kaiwen Chi, Luning Mao, Lixin Zhou, Dongmei Lin, Shaoping Ling
    Modern Pathology.2022; 35(3): 403.     CrossRef
  • Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies
    Matthew W. Rosenbaum, Raul S. Gonzalez
    Seminars in Diagnostic Pathology.2022; 39(1): 48.     CrossRef
  • Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches
    Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim
    Biomedicines.2022; 10(3): 543.     CrossRef
  • Development and validation of a supervised deep learning algorithm for automated whole‐slide programmed death‐ligand 1 tumour proportion score assessment in non‐small cell lung cancer
    Liesbeth M Hondelink, Melek Hüyük, Pieter E Postmus, Vincent T H B M Smit, Sami Blom, Jan H Thüsen, Danielle Cohen
    Histopathology.2022; 80(4): 635.     CrossRef
  • 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies
    Ziyad Alsugair, Vahan Kepenekian, Tanguy Fenouil, Olivier Glehen, Laurent Villeneuve, Sylvie Isaac, Juliette Hommell-Fontaine, Nazim Benzerdjeb
    Virchows Archiv.2022; 481(1): 23.     CrossRef
  • Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response
    Sangjoon Choi, Soo Ick Cho, Minuk Ma, Seonwook Park, Sergio Pereira, Brian Jaehong Aum, Seunghwan Shin, Kyunghyun Paeng, Donggeun Yoo, Wonkyung Jung, Chan-Young Ock, Se-Hoon Lee, Yoon-La Choi, Jin-Haeng Chung, Tony S. Mok, Hyojin Kim, Seokhwi Kim
    European Journal of Cancer.2022; 170: 17.     CrossRef
  • Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer
    Guoping Cheng, Fuchuang Zhang, Yishi Xing, Xingyi Hu, He Zhang, Shiting Chen, Mengdao Li, Chaolong Peng, Guangtai Ding, Dadong Zhang, Peilin Chen, Qingxin Xia, Meijuan Wu
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab
    Vipul Baxi, George Lee, Chunzhe Duan, Dimple Pandya, Daniel N. Cohen, Robin Edwards, Han Chang, Jun Li, Hunter Elliott, Harsha Pokkalla, Benjamin Glass, Nishant Agrawal, Abhik Lahiri, Dayong Wang, Aditya Khosla, Ilan Wapinski, Andrew Beck, Michael Montalt
    Modern Pathology.2022; 35(11): 1529.     CrossRef
  • High interobserver and intraobserver reproducibility among pathologists assessing PD‐L1 CPS across multiple indications
    Shanthy Nuti, Yiwei Zhang, Nabila Zerrouki, Charlotte Roach, Gudrun Bänfer, George L Kumar, Edward Manna, Rolf Diezko, Kristopher Kersch, Josef Rüschoff, Bharat Jasani
    Histopathology.2022; 81(6): 732.     CrossRef
  • Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer
    Alejandro Avilés‐Salas, Diana Flores‐Estrada, Luis Lara‐Mejía, Rodrigo Catalán, Graciela Cruz‐Rico, Mario Orozco‐Morales, David Heredia, Laura Bolaño‐Guerra, Pamela Denisse Soberanis‐Piña, Edgar Varela‐Santoyo, Andrés F. Cardona, Oscar Arrieta
    Thoracic Cancer.2022; 13(23): 3362.     CrossRef
  • A practical approach for PD-L1 evaluation in gastroesophageal cancer
    Valentina Angerilli, Matteo Fassan, Paola Parente, Irene Gullo, Michela Campora, Chiara Rossi, Maria Luisa Sacramento, Gianmaria Pennelli, Alessandro Vanoli, Federica Grillo, Luca Mastracci
    Pathologica.2022; : 1.     CrossRef
  • Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma
    Julia R. Naso, Gang Wang, Norbert Banyi, Fatemeh Derakhshan, Aria Shokoohi, Cheryl Ho, Chen Zhou, Diana N. Ionescu
    Annals of Diagnostic Pathology.2021; 50: 151590.     CrossRef
  • Interobserver agreement in programmed cell death‐ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens
    William Sinclair, Peter Kobalka, Rongqin Ren, Boulos Beshai, Abberly A. Lott Limbach, Lai Wei, Ping Mei, Zaibo Li
    Diagnostic Cytopathology.2021; 49(2): 219.     CrossRef
  • Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software
    Julia R. Naso, Tetiana Povshedna, Gang Wang, Norbert Banyi, Calum MacAulay, Diana N. Ionescu, Chen Zhou
    Pathology and Oncology Research.2021;[Epub]     CrossRef
  • The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation
    Angels Barberà, Ruth Marginet Flinch, Montserrat Martin, Jose L. Mate, Albert Oriol, Fina Martínez-Soler, Tomas Santalucia, Pedro L. Fernández
    Applied Immunohistochemistry & Molecular Morphology.2021; 29(1): 76.     CrossRef
  • Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
    Kyu Sang Lee, Gheeyoung Choe
    Journal of Pathology and Translational Medicine.2021; 55(3): 163.     CrossRef
  • Comparison of Semi-Quantitative Scoring and Artificial Intelligence Aided Digital Image Analysis of Chromogenic Immunohistochemistry
    János Bencze, Máté Szarka, Balázs Kóti, Woosung Seo, Tibor G. Hortobágyi, Viktor Bencs, László V. Módis, Tibor Hortobágyi
    Biomolecules.2021; 12(1): 19.     CrossRef
  • Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas
    Federica Riccardo, Giuseppina Barutello, Angela Petito, Lidia Tarone, Laura Conti, Maddalena Arigoni, Chiara Musiu, Stefania Izzo, Marco Volante, Dario Livio Longo, Irene Fiore Merighi, Mauro Papotti, Federica Cavallo, Elena Quaglino
    Vaccines.2020; 8(2): 166.     CrossRef
  • Utility of PD-L1 testing on non-small cell lung cancer cytology specimens: An institutional experience with interobserver variability analysis
    Oleksandr Kravtsov, Christopher P. Hartley, Yuri Sheinin, Bryan C. Hunt, Juan C. Felix, Tamara Giorgadze
    Annals of Diagnostic Pathology.2020; 48: 151602.     CrossRef
RETRACTION: eNOS Gene Polymorphisms in Perinatal Hypoxic-Ischemic Encephalopathy
J Pathol Transl Med. 2019;53(5):345-345.   Published online September 6, 2019
DOI: https://doi.org/10.4132/jptm.2019.09.06
Retracts: J Pathol Transl Med 2009;43(4):306
  • 5,843 View
  • 152 Download
  • 2 Citations
PDF

Citations

Citations to this article as recorded by  
  • Unjustified Authorship Should Not Be Tolerated
    Sung-Tae Hong
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Unjustified Authorship such as Gift Authorship for Your Kids: It Is a Crime, Professor.
    Seung-Kee Min
    Vascular Specialist International.2019; 35(4): 181.     CrossRef
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Dong Hoon Shin, Hyo Sup Shim, Tae Jung Kim, Heae Surng Park, Yun La Choi, Wan Seop Kim, Lucia Kim, Sun Hee Chang, Joon Seon Song, Hyo jin Kim, Jung Ho Han, Chang Hun Lee, Geon Kook Lee, Se Jin Jang
J Pathol Transl Med. 2019;53(3):153-158.   Published online February 28, 2019
DOI: https://doi.org/10.4132/jptm.2019.02.22
  • 5,880 View
  • 234 Download
  • 4 Citations
AbstractAbstract PDF
Liquid biopsy for detection of mutation from circulating tumor DNA is a new technology which is attractive in that it is non-invasive. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is an effective first line drug for advanced non-small cell lung cancer patients who harbor activating EGFR mutation. During the course of treatment, resistance against TKI arises which can be contributed to EGFR T790M mutation in about 50–60% of patients. Third generation TKI may overcome the resistance. In patients who cannot undergo tissue biopsy due to variable reasons, liquid biopsy is an excellent alternative for the detection of EGFR T790M mutation. However, this relatively novel method requires standardization and vigorous quality insurance. Thus, a standard set of guideline recommendations for liquid biopsy for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of provisional guideline recommendations that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by  
  • Exosomes in Lung Cancer: Actors and Heralds of Tumor Development
    Amaia Sandúa, Estibaliz Alegre, Álvaro González
    Cancers.2021; 13(17): 4330.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Current status and future perspectives of liquid biopsy in non-small cell lung cancer
    Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim
    Journal of Pathology and Translational Medicine.2020; 54(3): 204.     CrossRef
  • Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center
    Hazem Assi, Arafat Tfayli, Nada Assaf, Sarah Abou Daya, Aram H. Bidikian, Dima Kawsarani, Puzant Fermanian, Ghazi Zaatari, Rami Mahfouz
    Molecular Biology Reports.2019; 46(4): 3671.     CrossRef
Current Cytology Practices in Korea: A Nationwide Survey by the Korean Society for Cytopathology
Eun Ji Oh, Chan Kwon Jung, Dong-Hoon Kim, Han Kyeom Kim, Wan Seop Kim, So-Young Jin, Hye Kyoung Yoon
J Pathol Transl Med. 2017;51(6):579-587.   Published online September 27, 2017
DOI: https://doi.org/10.4132/jptm.2017.08.11
  • 6,144 View
  • 150 Download
  • 12 Citations
AbstractAbstract PDF
Background
Limited data are available on the current status of cytology practices in Korea. This nationwide study presents Korean cytology statistics from 2015.
Methods
A nationwide survey was conducted in 2016 as a part of the mandatory quality-control program by the Korean Society for Cytopathology. The questionnaire was sent to 208 medical institutions performing cytopathologic examinations in Korea. Individual institutions were asked to submit their annual cytology statistical reports and gynecologic cytology-histology correlation data for 2015.
Results
Responses were obtained from 206 medical institutions including 83 university hospitals, 87 general hospitals, and 36 commercial laboratories. A total of 8,284,952 cytologic examinations were performed in 2015, primarily in commercial laboratories (74.9%). The most common cytology specimens were gynecologic samples (81.3%). Conventional smears and liquid-based cytology were performed in 6,190,526 (74.7%) and 2,094,426 (25.3%) cases, respectively. The overall diagnostic concordance rate between cytologic and histologic diagnoses of uterine cervical samples was 70.5%. Discordant cases were classified into three categories: category A (minimal clinical impact, 17.4%), category B (moderate clinical impact, 10.2%), and category C (major clinical impact, 1.9%). The ratio of atypical squamous cells of undetermined significance to squamous intraepithelial lesion was 1.6 in university hospitals, 2.9 in general hospitals, and 4.9 in commercial laboratories.
Conclusions
This survey reveals the current status and trend of cytology practices in Korea. The results of this study can serve as basic data for the establishment of nationwide cytopathology policies and quality improvement guidelines in Korean medical institutions.

Citations

Citations to this article as recorded by  
  • Current state of cytopathology residency training: a Korean national survey of pathologists
    Uiju Cho, Tae Jung Kim, Wan Seop Kim, Kyo Young Lee, Hye Kyoung Yoon, Hyun Joo Choi
    Journal of Pathology and Translational Medicine.2023; 57(2): 95.     CrossRef
  • Recent Application of Artificial Intelligence in Non-Gynecological Cancer Cytopathology: A Systematic Review
    Nishant Thakur, Mohammad Rizwan Alam, Jamshid Abdul-Ghafar, Yosep Chong
    Cancers.2022; 14(14): 3529.     CrossRef
  • Re-Increasing Trends in Thyroid Cancer Incidence after a Short Period of Decrease in Korea: Reigniting the Debate on Ultrasound Screening
    Chan Kwon Jung, Ja Seong Bae, Young Joo Park
    Endocrinology and Metabolism.2022; 37(5): 816.     CrossRef
  • Diagnostic distribution and pitfalls of glandular abnormalities in cervical cytology: a 25-year single-center study
    Jung-A Sung, Ilias P. Nikas, Haeryoung Kim, Han Suk Ryu, Cheol Lee
    Journal of Pathology and Translational Medicine.2022; 56(6): 354.     CrossRef
  • Current status of cytopathology practice in Korea: impact of the coronavirus pandemic on cytopathology practice
    Soon Auck Hong, Haeyoen Jung, Sung Sun Kim, Min-Sun Jin, Jung-Soo Pyo, Ji Yun Jeong, Younghee Choi, Gyungyub Gong, Yosep Chong
    Journal of Pathology and Translational Medicine.2022; 56(6): 361.     CrossRef
  • Systematic screening for cervical cancer in Dakar region: prevalence and correlation with biological and socio-demographic parameters
    Dominique Diouf, Gora Diop, Cheikh Ahmadou Tidian Diarra, Aminata Issa Ngom, Khadija Niane, Moussa Ndiaye, Sidy Ka, Oumar Faye, Ahmadou Dem
    Infectious Agents and Cancer.2020;[Epub]     CrossRef
  • Continuous quality improvement program and its results of Korean Society for Cytopathology
    Yoo-Duk Choi, Hoon-Kyu Oh, Su-Jin Kim, Kyung-Hee Kim, Yun-Kyung Lee, Bo-Sung Kim, Eun-Jeong Jang, Yoon-Jung Choi, Eun-Kyung Han, Dong-Hoon Kim, Younghee Choi, Chan-Kwon Jung, Sung-Nam Kim, Kyueng-Whan Min, Seok-Jin Yoon, Hun-Kyung Lee, Kyung Un Choi, Hye
    Journal of Pathology and Translational Medicine.2020; 54(3): 246.     CrossRef
  • Current status of cytopathology practices in Korea: annual report on the Continuous Quality Improvement program of the Korean Society for Cytopathology for 2018
    Yosep Chong, Haeyoen Jung, Jung-Soo Pyo, Soon Won Hong, Hoon Kyu Oh
    Journal of Pathology and Translational Medicine.2020; 54(4): 318.     CrossRef
  • Current Status of and Perspectives on Cervical Cancer Screening in Korea
    Sung-Chul Lim, Chong Woo Yoo
    Journal of Pathology and Translational Medicine.2019; 53(4): 210.     CrossRef
  • Cytomorphological Features of Hyperchromatic Crowded Groups in Liquid-Based Cervicovaginal Cytology: A Single Institutional Experience
    Youngeun Lee, Cheol Lee, In Ae Park, Hyoung Jin An, Haeryoung Kim
    Journal of Pathology and Translational Medicine.2019; 53(6): 393.     CrossRef
  • Comparison Study of the Adequacy and Pain Scale of Ultrasound-Guided Fine-Needle Aspiration of Solid Thyroid Nodules with a 21- or 23-Gauge Needle for Liquid-Based Cytology: a Single-Center Study
    Soo Jin Jung, Dong Wook Kim, Hye Jin Baek
    Endocrine Pathology.2018; 29(1): 30.     CrossRef
  • Thyroid Fine-Needle Aspiration Cytology Practice in Korea
    Yoon Jin Cha, Ju Yeon Pyo, SoonWon Hong, Jae Yeon Seok, Kyung-Ju Kim, Jee-Young Han, Jeong Mo Bae, Hyeong Ju Kwon, Yeejeong Kim, Kyueng-Whan Min, Soonae Oak, Sunhee Chang
    Journal of Pathology and Translational Medicine.2017; 51(6): 521.     CrossRef
Epstein-Barr Virus–Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification
Hyun-Jung Kim, Young Hyeh Ko, Ji Eun Kim, Seung-Sook Lee, Hyekyung Lee, Gyeongsin Park, Jin Ho Paik, Hee Jeong Cha, Yoo-Duk Choi, Jae Ho Han, Jooryung Huh
J Pathol Transl Med. 2017;51(4):352-358.   Published online June 5, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.15
  • 14,035 View
  • 937 Download
  • 53 Citations
AbstractAbstract PDF
Epstein-Barr virus (human herpesvirus-4) is very common virus that can be detected in more than 95% of the human population. Most people are asymptomatic and live their entire lives in a chronically infected state (IgG positive). However, in some populations, the Epstein-Barr virus (EBV) has been involved in the occurrence of a wide range of B-cell lymphoproliferative disorders (LPDs), including Burkitt lymphoma, classic Hodgkin’s lymphoma, and immune–deficiency associated LPDs (post-transplant and human immunodeficiency virus–associated LPDs). T-cell LPDs have been reported to be associated with EBV with a subset of peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphomas, extranodal nasal natural killer/T-cell lymphomas, and other rare histotypes. This article reviews the current evidence covering EBV-associated LPDs based on the 2016 classification of the World Health Organization. These LPD entities often pose diagnostic challenges, both clinically and pathologically, so it is important to understand their unique pathophysiology for correct diagnoses and optimal management.

Citations

Citations to this article as recorded by  
  • Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer
    Al-Hassan M. Mustafa, Oliver H. Krämer, Lynette Daws
    Pharmacological Reviews.2023; 75(1): 35.     CrossRef
  • Autophagy-associated immune dysregulation and hyperplasia in a patient with compound heterozygous mutations in ATG9A
    Guowu Hu, Pia J Hauk, Nannan Zhang, Waleed Elsegeiny, Carlos M. Guardia, Amy Kullas, Kevin Crosby, Robin R. Deterding, Michaela Schedel, Paul Reynolds, Jordan K Abbott, Vijaya Knight, Stefania Pittaluga, Mark Raffeld, Sergio D. Rosenzweig, Juan S. Bonifac
    Autophagy.2023; 19(2): 678.     CrossRef
  • Primary head and neck cancer cell cultures are susceptible to proliferation of Epstein-Barr virus infected lymphocytes
    Senyao Shao, Lars Uwe Scholtz, Sarah Gendreizig, Laura Martínez-Ruiz, Javier Florido, Germaine Escames, Matthias Schürmann, Carsten Hain, Leonie Hose, Almut Mentz, Pascal Schmidt, Menghang Wang, Peter Goon, Michael Wehmeier, Frank Brasch, Jörn Kalinowski,
    BMC Cancer.2023;[Epub]     CrossRef
  • Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis
    Yaxian Ma, Peiling Zhang, Yuhan Bao, Hui Luo, Jiachen Wang, Liang Huang, Miao Zheng
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Successful treatment by using a modified SMILE regimen and autologous hematopoietic stem cell transplantation in a pediatric primary EBV-positive nodular NK/T cell lymphoma patient
    Jian Li, Juxin Ye, Yongren Wang, Jun Wang, Yongjun Fang
    Annals of Hematology.2022; 101(2): 433.     CrossRef
  • Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders
    Lisa R. Forbes, Olive S. Eckstein, Nitya Gulati, Erin C. Peckham-Gregory, Nmazuo W. Ozuah, Joseph Lubega, Nader K. El-Mallawany, Jennifer E. Agrusa, M. Cecilia Poli, Tiphanie P. Vogel, Natalia S. Chaimowitz, Nicholas L. Rider, Emily M. Mace, Jordan S. Ora
    Journal of Allergy and Clinical Immunology.2022; 149(2): 758.     CrossRef
  • EBV-positive B-cell ulcerative proliferation in the oral cavity associated with EBV-negative follicular lymphoma in a patient with common variable immunodeficiency: A case report and review of the literature
    Waleed A. Alamoudi, Antoine Azar, Stefan K. Barta, Faizan Alawi, Takako I. Tanaka, Eric T. Stoopler, Thomas P. Sollecito
    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2022; 133(1): e10.     CrossRef
  • Necrotizing Follicular Lymphoma of the Inguinal Region with Sternbergoid Cells: Clinical–Pathological Features of a Challenging Entity
    Federico Scarmozzino, Marco Pizzi, Marta Sbaraglia, Luisa Santoro, Luca Frison, Silvia Nalio, Laura Bonaldi, Livio Trentin, Angelo Paolo Dei Tos
    Applied Sciences.2022; 12(3): 1290.     CrossRef
  • High percentages of peripheral blood T-cell activation in childhood Hodgkin's lymphoma are associated with inferior outcome
    Fengqing Cai, Hui Gao, Zhongsheng Yu, Kun Zhu, Weizhong Gu, Xiaoping Guo, Xiaojun Xu, Hongqiang Shen, Qiang Shu
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Case Report of a Novel NFkB Mutation in a Lymphoproliferative Disorder Patient
    Khashayar Danandeh, Parnian Jabbari, Elham Rayzan, Samaneh Zoghi, Sepideh Shahkarami, Raul Jimenez Heredia, Ana Krolo, Bibi Shahin Shamsian, Kaan Boztug, Nima Rezaei
    Endocrine, Metabolic & Immune Disorders - Drug Targets.2022; 22(10): 1040.     CrossRef
  • When to suspect inborn errors of immunity in Epstein–Barr virus–related lymphoproliferative disorders
    Keith A. Sacco, Luigi D. Notarangelo, Ottavia M. Delmonte
    Clinical Microbiology and Infection.2022;[Epub]     CrossRef
  • EBV-associated diseases: Current therapeutics and emerging technologies
    Srishti Chakravorty, Behdad Afzali, Majid Kazemian
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Clinical and genetic characterization of Epstein-Barr virus–associated T/NK-cell lymphoproliferative diseases
    Hui Luo, Dan Liu, Wenbing Liu, Jin Jin, Xiaoman Bi, Peiling Zhang, Jia Gu, Miao Zheng, Min Xiao, Xin Liu, Jianfeng Zhou, Qian-Fei Wang
    Journal of Allergy and Clinical Immunology.2022;[Epub]     CrossRef
  • Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders
    Akihiro Ohmoto, Shigeo Fuji
    Blood Reviews.2021; 49: 100807.     CrossRef
  • Comparative Study on Epstein-Barr Virus-Positive Mucocutaneous Ulcer and Methotrexate-Associated Lymphoproliferative Disorders Developed in the Oral Mucosa: A Case Series of 10 Patients and Literature Review
    Kyoichi Obata, Tatsuo Okui, Sawako Ono, Koki Umemori, Shoji Ryumon, Kisho Ono, Mayumi Yao, Norie Yoshioka, Soichiro Ibaragi, Akira Sasaki
    Diagnostics.2021; 11(8): 1375.     CrossRef
  • Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis
    Justin J. Kuhlman, Muhamad Alhaj Moustafa, Alexander J. Tun, David M. Menke, Han W. Tun, Liuyan Jiang
    Clinical Case Reports.2021;[Epub]     CrossRef
  • Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis
    Shimaa Hassan AbdelAziz Soliman, Arturo Orlacchio, Fabio Verginelli
    Microorganisms.2021; 9(6): 1179.     CrossRef
  • Spontaneous regression of chronic epstein –Barr virus infection-related lymphoproliferative disease
    Bharti Kumari, Akshata Rao, ManickaSaravanan Subramanian, AparajitBallav Dey
    Journal of the Indian Academy of Geriatrics.2021; 17(1): 40.     CrossRef
  • The Pivotal Role of Viruses in the Pathogeny of Chronic Lymphocytic Leukemia: Monoclonal (Type 1) IgG K Cryoglobulinemia and Chronic Lymphocytic Leukemia Diagnosis in the Course of a Human Metapneumovirus Infection
    Jérémy Barben, Alain Putot, Anca-Maria Mihai, Jérémie Vovelle, Patrick Manckoundia
    Viruses.2021; 13(1): 115.     CrossRef
  • B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
    Maria T. Cencioni, Miriam Mattoscio, Roberta Magliozzi, Amit Bar-Or, Paolo A. Muraro
    Nature Reviews Neurology.2021; 17(7): 399.     CrossRef
  • Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts
    Laura J. Janke, Denise M. Imai, Heather Tillman, Rosalinda Doty, Mark J. Hoenerhoff, Jiajie J. Xu, Zachary T. Freeman, Portia Allen, Natalie Wall Fowlkes, Ilaria Iacobucci, Kirsten Dickerson, Charles G. Mullighan, Peter Vogel, Jerold E. Rehg
    Veterinary Pathology.2021; 58(1): 181.     CrossRef
  • Viral coinfections in COVID‐19
    Parisa S. Aghbash, Narges Eslami, Milad Shirvaliloo, Hossein B. Baghi
    Journal of Medical Virology.2021; 93(9): 5310.     CrossRef
  • Genetic predisposition to lymphomas: Overview of rare syndromes and inherited familial variants
    Bartosz Szmyd, Wojciech Mlynarski, Agata Pastorczak
    Mutation Research/Reviews in Mutation Research.2021; 788: 108386.     CrossRef
  • Acute Epstein‐Barr virus associated haemophagocytosis in an Asian female: What is the diagnosis?
    Soumya Ojha, Guiyi Ho, Cheryl X. Q. Lim, Siok B. Ng, Sanjay Mel
    American Journal of Hematology.2021; 96(11): 1541.     CrossRef
  • Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
    Xinle Cui, Clifford M. Snapper
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma
    Mostafa F. Mohammed Saleh, Ahmed Kotb, Ghada E. M. Abdallah, Ibrahim N. Muhsen, Riad El Fakih, Mahmoud Aljurf
    Current Oncology.2021; 28(6): 5480.     CrossRef
  • Intestinal ulcers as an initial finding in EBV-associated lymphoproliferative disorder
    Sizhu Wang, Yinghuan Dai, Jie Zhang, Dalian Ou, Chunhui Ouyang, Fanggen Lu
    Medicine.2020; 99(3): e18764.     CrossRef
  • Microbes as Master Immunomodulators: Immunopathology, Cancer and Personalized Immunotherapies
    Joana R. Lérias, Georgia Paraschoudi, Eric de Sousa, João Martins, Carolina Condeço, Nuno Figueiredo, Carlos Carvalho, Ernest Dodoo, Mireia Castillo-Martin, Antonio Beltrán, Dário Ligeiro, Martin Rao, Alimuddin Zumla, Markus Maeurer
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Epstein Barr Virus-associated Pediatric Neoplasms
    Mozhgan Hashemieh, Fariba Shirvani
    Archives of Pediatric Infectious Diseases.2020;[Epub]     CrossRef
  • Novel IRF8 and PD-L1 molecular aberrations in systemic EBV-positive T-cell lymphoma of childhood
    Atif Saleem, Rohan Joshi, Li Lei, Lhara Lezama, Shyam S. Raghavan, Nastaran Neishaboori, Mohana Roy, Joe Schroers-Martin, Gregory W. Charville, Christian Kunder, Brent Tan, Beth A. Martin, Yasodha Natkunam
    Human Pathology: Case Reports.2020; 19: 200356.     CrossRef
  • Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease
    Luca Roncati, Beatrice Lusenti, Vincenzo Nasillo, Antonio Manenti
    Annals of Hematology.2020; 99(8): 1945.     CrossRef
  • Epstein-Barr Virus and the Eye
    Emmett T. Cunningham, Manfred Zierhut
    Ocular Immunology and Inflammation.2020; 28(4): 533.     CrossRef
  • An atypical systemic form of chronic active EBV infection
    Neha Gupta, Adam Bagg
    Leukemia & Lymphoma.2020; 61(12): 3030.     CrossRef
  • A Shared TCR Bias toward an Immunogenic EBV Epitope Dominates in HLA-B*07:02–Expressing Individuals
    Louise C. Rowntree, Thi H. O. Nguyen, Carine Farenc, Hanim Halim, Luca Hensen, Jamie Rossjohn, Tom C. Kotsimbos, Anthony W. Purcell, Katherine Kedzierska, Stephanie Gras, Nicole A. Mifsud
    The Journal of Immunology.2020; 205(6): 1524.     CrossRef
  • Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis
    Haijuan Xiao, Bing Hu, Rongmu Luo, Huili Hu, Junmei Zhang, Weiying Kuang, Rui Zhang, Li Li, Gang Liu
    Virology Journal.2020;[Epub]     CrossRef
  • Epstein-Barr Virus (EBV)-induced B-cell Lymphoproliferative Disorder Mimicking the Recurrence of EBV-associated Hemophagocytic Lymphohistiocytosis
    Yuki Yatsushiro, Takuro Nishikawa, Aki Saito, Yozo Nakazawa, Ken-Ichi Imadome, Shunsuke Nakagawa, Yuichi Kodama, Yasuhiro Okamoto, Hirokazu Kanegane, Yoshifumi Kawano
    Journal of Pediatric Hematology/Oncology.2019; 41(1): e44.     CrossRef
  • Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
    Moussab Tatfi, Olivier Hermine, Felipe Suarez
    Frontiers in Immunology.2019;[Epub]     CrossRef
  • The factors associated with the early diagnosis of nasal NK/T-cell lymphoma with prominent ocular symptoms and general nasal NKTL
    Zhen zhen Hu, Ying Wang
    American Journal of Otolaryngology.2019; 40(3): 353.     CrossRef
  • Unusual lymphoid malignancy and treatment response in two children with Down syndrome
    Ashley Geerlinks, Jennifer Keis, Bo Ngan, Amer Shammas, Reza Vali, Johann Hitzler
    Pediatric Blood & Cancer.2019;[Epub]     CrossRef
  • Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL)
    Kelsey Sokol, Saritha Kartan, William T. Johnson, Onder Alpdogan, Neda Nikbakht, Bradley M. Haverkos, Jerald Gong, Pierluigi Porcu
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments
    Hani Nakhoul, Zhen Lin, Xia Wang, Claire Roberts, Yan Dong, Erik Flemington, Blossom Damania
    mSphere.2019;[Epub]     CrossRef
  • Quercetin Interrupts the Positive Feedback Loop Between STAT3 and IL-6, Promotes Autophagy, and Reduces ROS, Preventing EBV-Driven B Cell Immortalization
    Granato, Gilardini Montani, Zompetta, Santarelli, Gonnella, Romeo, D’Orazi, Faggioni, Cirone
    Biomolecules.2019; 9(9): 482.     CrossRef
  • Diffuse Large B-Cell Lymphoma Arising within Ileal Neobladder: An Expanding Spectrum of Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation
    Hyekyung Lee, Hyunbin Shin, Nae Yu Kim, Hyun Sik Park, Jinsung Park
    Cancer Research and Treatment.2019; 51(4): 1666.     CrossRef
  • EBV-associated lymphoproliferative disorder involving the gastrointestinal tract which mimic IBD in immunocompetent patients: case reports and literature review
    Yanhua Zhou, Yanlin Zhang, Haiying Zhao, Xuan Cui, Yongqiu Wei, Yongdong Wu, Shutian Zhang, Ye Zong
    International Journal of Colorectal Disease.2019; 34(11): 1989.     CrossRef
  • Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas
    Jungang Chen, Samantha Kendrick, Zhiqiang Qin
    Viruses.2019; 11(12): 1161.     CrossRef
  • Rapidly Fatal Encephalitis Associated with Atypical Lymphoid Proliferations of the Basal Ganglia Subsequent to Aneurysmal Subarachnoid Hemorrhage
    Ayesha Kar, Evin L. Guilliams, Joshua A. Cuoco, Eric A. Marvin
    Clinics and Practice.2019; 9(4): 1187.     CrossRef
  • Clinicopathologic features of adult EBV-associated B-cell lymphoproliferative disease
    Sonja Wörner, Hans-Konrad Mueller-Hermelink, Hans-Ullrich Voelker
    Pathology - Research and Practice.2018; 214(2): 207.     CrossRef
  • Primary Intestinal Epstein–Barr Virus-associated Natural Killer/T-cell Lymphoproliferative Disorder: A Disease Mimicking Inflammatory Bowel Disease
    Zhujun Wang, Wenyan Zhang, Chengxin Luo, Min Zhu, Yu Zhen, Jingxi Mu, Yan Zhang, Renwei Hu, Yufang Wang, Zhonghui Wen, Qin Ouyang, Shuyuan Xiao, Hu Zhang
    Journal of Crohn's and Colitis.2018; 12(8): 896.     CrossRef
  • Downregulation of CD5 and dysregulated CD8+T-cell activation
    Taizo Wada
    Pediatrics International.2018; 60(9): 776.     CrossRef
  • Chronic active Epstein-Barr virus infection of T-cell type, systemic form in an African migrant: case report and review of the literature on diagnostics standards and therapeutic options
    Maxi Wass, Marcus Bauer, Roald Pfannes, Kerstin Lorenz, Andreas Odparlik, Lutz P Müller, Claudia Wickenhauser
    BMC Cancer.2018;[Epub]     CrossRef
  • Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
    Edit Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, Bettina Gisslinger, Zsuzsanna Bago-Horvath, Emilio Casanova-Hevia, Emmanuelle Clappier, Thomas Decker, Sabine Fajmann, Daniela A. Fux, Georg Greiner, Sinan Gueltekin, Gerwin Heller, Harald Herkner, Gr
    Blood.2018; 132(7): 694.     CrossRef
  • Gammaherpesviral infections in patients with immunological disorders
    Anna Żuk-Wasek, Maciej Przybylski, Natalia Żeber, Grażyna Młynarczyk, Tomasz Dzieciątkowski
    Postępy Mikrobiologii - Advancements of Microbiology.2018; 57(2): 145.     CrossRef
  • COMPARATIVE ANALYSIS OF SEROLOGICAL MARKERS OF HERPES VIRUSES AND QUANTITATIVE IMMUNOGLOBULINOPATHIES IN PRIMARY PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
    N. G. Chernova, D. S. Tihomirov, N. P. Soboleva, S. A. Mariina, Y. V. Sidorova, M. N. Sinitsyna, V. N. Dvirnyk, S. M. Kulikov, T. A. Tupoleva, E. E. Zvonkov
    Problems of Virology.2018; 63(4): 171.     CrossRef
Molecular Testing of Lung Cancers
Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
J Pathol Transl Med. 2017;51(3):242-254.   Published online April 21, 2017
DOI: https://doi.org/10.4132/jptm.2017.04.10
  • 12,834 View
  • 552 Download
  • 21 Citations
AbstractAbstract PDF
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.

Citations

Citations to this article as recorded by  
  • Molecular Pathology of Lung Cancer
    James J. Saller, Theresa A. Boyle
    Cold Spring Harbor Perspectives in Medicine.2022; 12(3): a037812.     CrossRef
  • Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
    Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(5): 249.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
    Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee, Kyoung Song, Hannah Lee, Ryong Nam Kim, Young Kee Shin, Doo-Yi Oh, Yoon-La Choi
    Cancer Research and Treatment.2021; 53(1): 9.     CrossRef
  • The promises and challenges of early non‐small cell lung cancer detection: patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers
    Lukas Kalinke, Ricky Thakrar, Sam M. Janes
    Molecular Oncology.2021; 15(10): 2544.     CrossRef
  • Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
    Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park, Chanhyun Park
    Expert Review of Pharmacoeconomics & Outcomes Research.2021; 21(3): 381.     CrossRef
  • The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
    Parth Shah, Jacob Sands, Nicola Normanno
    Lung Cancer.2021; 160: 118.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
    Melina E. Marmarelis, Corey J. Langer
    Clinical Lung Cancer.2020; 21(5): 395.     CrossRef
  • Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
    Eunhyang Park, Hyo Sup Shim
    Cancer Research and Treatment.2020; 52(2): 543.     CrossRef
  • High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
    Yuyin Xu, Heng Chang, Lijing Wu, Xin Zhang, Ling Zhang, Jing Zhang, Yuan Li, Lei Shen, Xiaoli Zhu, Xiaoyan Zhou, Qianming Bai
    Experimental and Molecular Pathology.2020; 117: 104548.     CrossRef
  • An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
    Jiacong Wei, Anna A. Rybczynska, Pei Meng, Martijn Terpstra, Ali Saber, Jantine Sietzema, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry. J.M. Groen, Anthonie van der Wekken, Anke van den Berg, Klaas Kok
    Cancers.2020; 12(10): 2843.     CrossRef
  • Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
    Alexander Gavralidis, Justin F. Gainor
    The Cancer Journal.2020; 26(6): 517.     CrossRef
  • Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors
    Jasna Metovic, Luisella Righi, Luisa Delsedime, Marco Volante, Mauro Papotti
    Acta Cytologica.2020; 64(1-2): 16.     CrossRef
  • Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer
    Eun Kyung Kim, Kyung A. Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim
    Clinical Lung Cancer.2019; 20(1): e123.     CrossRef
  • PD-L1 expression inROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening ofEGFR,ALK, andROS1
    Jongmin Lee, Chan Kwon Park, Hyoung-Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae-Jung Kim
    Thoracic Cancer.2019; 10(1): 103.     CrossRef
  • Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
    Yeon Bi Han, Hyun Jung Kwon, Soo Young Park, Eun-Sun Kim, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2019; 53(2): 86.     CrossRef
  • Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
    Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
    Lung Cancer.2019; 136: 65.     CrossRef
  • Somatic mutations and immune checkpoint biomarkers
    Brielle A. Parris, Eloise Shaw, Brendan Pang, Richie Soong, Kwun Fong, Ross A. Soo
    Respirology.2019; 24(3): 215.     CrossRef
  • Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
    Anna Chalmers, Laura Cannon, Wallace Akerley
    The Oncologist.2019; 24(7): 963.     CrossRef
  • Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces
    Jae Seok Lee, Eun Kyung Kim, Moonsik Kim, Hyo Sup Shim
    Lung Cancer.2018; 123: 121.     CrossRef
Molecular Testing of Lung Cancers
Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
J Pathol Transl Med. 2017;51(3):242-254.   Published online April 21, 2017
DOI: https://doi.org/10.4132/jptm.2017.04.10
  • 12,834 View
  • 552 Download
  • 21 Citations
AbstractAbstract PDF
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.

Citations

Citations to this article as recorded by  
  • Molecular Pathology of Lung Cancer
    James J. Saller, Theresa A. Boyle
    Cold Spring Harbor Perspectives in Medicine.2022; 12(3): a037812.     CrossRef
  • Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
    Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(5): 249.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
    Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee, Kyoung Song, Hannah Lee, Ryong Nam Kim, Young Kee Shin, Doo-Yi Oh, Yoon-La Choi
    Cancer Research and Treatment.2021; 53(1): 9.     CrossRef
  • The promises and challenges of early non‐small cell lung cancer detection: patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers
    Lukas Kalinke, Ricky Thakrar, Sam M. Janes
    Molecular Oncology.2021; 15(10): 2544.     CrossRef
  • Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
    Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park, Chanhyun Park
    Expert Review of Pharmacoeconomics & Outcomes Research.2021; 21(3): 381.     CrossRef
  • The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
    Parth Shah, Jacob Sands, Nicola Normanno
    Lung Cancer.2021; 160: 118.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
    Melina E. Marmarelis, Corey J. Langer
    Clinical Lung Cancer.2020; 21(5): 395.     CrossRef
  • Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
    Eunhyang Park, Hyo Sup Shim
    Cancer Research and Treatment.2020; 52(2): 543.     CrossRef
  • High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
    Yuyin Xu, Heng Chang, Lijing Wu, Xin Zhang, Ling Zhang, Jing Zhang, Yuan Li, Lei Shen, Xiaoli Zhu, Xiaoyan Zhou, Qianming Bai
    Experimental and Molecular Pathology.2020; 117: 104548.     CrossRef
  • An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
    Jiacong Wei, Anna A. Rybczynska, Pei Meng, Martijn Terpstra, Ali Saber, Jantine Sietzema, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry. J.M. Groen, Anthonie van der Wekken, Anke van den Berg, Klaas Kok
    Cancers.2020; 12(10): 2843.     CrossRef
  • Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
    Alexander Gavralidis, Justin F. Gainor
    The Cancer Journal.2020; 26(6): 517.     CrossRef
  • Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors
    Jasna Metovic, Luisella Righi, Luisa Delsedime, Marco Volante, Mauro Papotti
    Acta Cytologica.2020; 64(1-2): 16.     CrossRef
  • Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer
    Eun Kyung Kim, Kyung A. Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim
    Clinical Lung Cancer.2019; 20(1): e123.     CrossRef
  • PD-L1 expression inROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening ofEGFR,ALK, andROS1
    Jongmin Lee, Chan Kwon Park, Hyoung-Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae-Jung Kim
    Thoracic Cancer.2019; 10(1): 103.     CrossRef
  • Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
    Yeon Bi Han, Hyun Jung Kwon, Soo Young Park, Eun-Sun Kim, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2019; 53(2): 86.     CrossRef
  • Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
    Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
    Lung Cancer.2019; 136: 65.     CrossRef
  • Somatic mutations and immune checkpoint biomarkers
    Brielle A. Parris, Eloise Shaw, Brendan Pang, Richie Soong, Kwun Fong, Ross A. Soo
    Respirology.2019; 24(3): 215.     CrossRef
  • Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
    Anna Chalmers, Laura Cannon, Wallace Akerley
    The Oncologist.2019; 24(7): 963.     CrossRef
  • Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces
    Jae Seok Lee, Eun Kyung Kim, Moonsik Kim, Hyo Sup Shim
    Lung Cancer.2018; 123: 121.     CrossRef
Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests
Jihun Kim, Woong-Yang Park, Nayoung K. D. Kim, Se Jin Jang, Sung-Min Chun, Chang-Ohk Sung, Jene Choi, Young-Hyeh Ko, Yoon-La Choi, Hyo Sup Shim, Jae-Kyung Won
J Pathol Transl Med. 2017;51(3):191-204.   Published online May 10, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.14
  • 21,777 View
  • 1,032 Download
  • 28 Citations
AbstractAbstract PDF
Next-generation sequencing (NGS) has recently emerged as an essential component of personalized cancer medicine due to its high throughput and low per-base cost. However, no sufficient guidelines for implementing NGS as a clinical molecular pathology test are established in Korea. To ensure clinical grade quality without inhibiting adoption of NGS, a taskforce team assembled by the Korean Society of Pathologists developed laboratory guidelines for NGS cancer panel testing procedures and requirements for clinical implementation of NGS. This consensus standard proposal consists of two parts: laboratory guidelines and requirements for clinical NGS laboratories. The laboratory guidelines part addressed several important issues across multistep NGS cancer panel tests including choice of gene panel and platform, sample handling, nucleic acid management, sample identity tracking, library preparation, sequencing, analysis and reporting. Requirements for clinical NGS tests were summarized in terms of documentation, validation, quality management, and other required written policies. Together with appropriate pathologist training and international laboratory standards, these laboratory standards would help molecular pathology laboratories to successfully implement NGS cancer panel tests in clinic. In this way, the oncology community would be able to help patients to benefit more from personalized cancer medicine.

Citations

Citations to this article as recorded by  
  • Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study
    Mustafa Umit Oner, Jianbin Chen, Egor Revkov, Anne James, Seow Ye Heng, Arife Neslihan Kaya, Jacob Josiah Santiago Alvarez, Angela Takano, Xin Min Cheng, Tony Kiat Hon Lim, Daniel Shao Weng Tan, Weiwei Zhai, Anders Jacobsen Skanderup, Wing-Kin Sung, Hwee
    Patterns.2022; 3(2): 100399.     CrossRef
  • Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
    Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
    Diagnostics.2022; 12(2): 409.     CrossRef
  • Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data
    Chad M. Vanderbilt, Anita S. Bowman, Sumit Middha, Kseniya Petrova-Drus, Yi-Wei Tang, Xin Chen, Youxiang Wang, Jason Chang, Natasha Rekhtman, Klaus J. Busam, Sounak Gupta, Meera Hameed, Maria E. Arcila, Marc Ladanyi, Michael F. Berger, Snjezana Dogan, Ahm
    The Journal of Molecular Diagnostics.2022; 24(5): 515.     CrossRef
  • Performance Evaluation of Three DNA Sample Tracking Tools in a Whole Exome Sequencing Workflow
    Gertjan Wils, Céline Helsmoortel, Pieter-Jan Volders, Inge Vereecke, Mauro Milazzo, Jo Vandesompele, Frauke Coppieters, Kim De Leeneer, Steve Lefever
    Molecular Diagnosis & Therapy.2022; 26(4): 411.     CrossRef
  • Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development
    Timothé Ménard, Alaina Barros, Christopher Ganter
    Therapeutic Innovation & Regulatory Science.2021; 55(5): 1066.     CrossRef
  • Fast Healthcare Interoperability Resources (FHIR)–Based Quality Information Exchange for Clinical Next-Generation Sequencing Genomic Testing: Implementation Study
    Donghyeong Seong, Sungwon Jung, Sungchul Bae, Jongsuk Chung, Dae-Soon Son, Byoung-Kee Yi
    Journal of Medical Internet Research.2021; 23(4): e26261.     CrossRef
  • Status of Next-Generation Sequencing-Based Genetic Diagnosis in Hematologic Malignancies in Korea (2017-2018)
    JinJu Kim, Ja Young Lee, Jungwon Huh, Myung-Hyun Nam, Myungshin Kim, Young-Uk Cho, Sun-Young Kong, Seung-Tae Lee, In-Suk Kim
    Laboratory Medicine Online.2021; 11(1): 25.     CrossRef
  • MSI-Testung
    Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, Wolfgang Dietmaier, Manfred Dietel, Arndt Hartmann, Lars-Christian Horn, Korinna Jöhrens, Thomas Kirchner, Ruth Knüchel, Doris Mayr, Sabine Merkelbach-Bruse, Hans-Ulrich Schildhaus, Peter Schirmacher, Mark
    Der Pathologe.2021; 42(4): 414.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • MSI testing
    Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, Wolfgang Dietmaier, Manfred Dietel, Arndt Hartmann, Lars-Christian Horn, Korinna Jöhrens, Thomas Kirchner, Ruth Knüchel, Doris Mayr, Sabine Merkelbach-Bruse, Hans-Ulrich Schildhaus, Peter Schirmacher, Mark
    Der Pathologe.2021; 42(S1): 110.     CrossRef
  • 16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer
    Huisong Lee, Hyeon Kook Lee, Seog Ki Min, Won Hee Lee
    World Journal of Surgical Oncology.2020;[Epub]     CrossRef
  • Risk Stratification Using a Novel Genetic Classifier Including PLEKHS1 Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
    Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
    Thyroid.2020; 30(11): 1589.     CrossRef
  • Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape
    Anurag Mehta, Smreti Vasudevan, Sanjeev Kumar Sharma, Manoj Panigrahi, Moushumi Suryavanshi, Mumtaz Saifi, Ullas Batra
    Applied Cancer Research.2020;[Epub]     CrossRef
  • Application Areas of Traditional Molecular Genetic Methods and NGS in relation to Hereditary Urological Cancer Diagnosis
    Dmitry S. Mikhaylenko, Alexander S. Tanas, Dmitry V. Zaletaev, Marina V. Nemtsova
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Assembling and Validating Bioinformatic Pipelines for Next-Generation Sequencing Clinical Assays
    Jeffrey A SoRelle, Megan Wachsmann, Brandi L. Cantarel
    Archives of Pathology & Laboratory Medicine.2020; 144(9): 1118.     CrossRef
  • Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples
    Erica K. Barnell, Peter Ronning, Katie M. Campbell, Kilannin Krysiak, Benjamin J. Ainscough, Lana M. Sheta, Shahil P. Pema, Alina D. Schmidt, Megan Richters, Kelsy C. Cotto, Arpad M. Danos, Cody Ramirez, Zachary L. Skidmore, Nicholas C. Spies, Jasreet Hun
    Genetics in Medicine.2019; 21(4): 972.     CrossRef
  • A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously
    Zoltán A. Mezei, Dávid Tornai, Róza Földesi, László Madar, Andrea Sümegi, Mária Papp, Péter Antal-Szalmás
    Journal of Biotechnology.2019; 303: 25.     CrossRef
  • Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges
    Hippman, Nislow
    Journal of Personalized Medicine.2019; 9(3): 40.     CrossRef
  • Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study
    Dohee Kwon, Binnari Kim, Hyeong Chan Shin, Eun Ji Kim, Sang Yun Ha, Kee-Taek Jang, Seung Tae Kim, Jeeyun Lee, Won Ki Kang, Joon Oh Park, Kyoung-Mee Kim
    Translational Oncology.2019; 12(11): 1488.     CrossRef
  • Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA
    Mancini, Simi, Salvianti, Castiglione, Sonnati, Pinzani
    Diagnostics.2019; 9(3): 117.     CrossRef
  • Benchmark Database for Process Optimization and Quality Control of Clinical Cancer Panel Sequencing
    Donghyeong Seong, Jongsuk Chung, Ki-Wook Lee, Sook-Young Kim, Byung-Suk Kim, Jung-Keun Song, Sungwon Jung, Taeseob Lee, Donghyun Park, Byoung-Kee Yi, Woong-Yang Park, Dae-Soon Son
    Biotechnology and Bioprocess Engineering.2019; 24(5): 793.     CrossRef
  • Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients
    Simon Heeke, Véronique Hofman, Elodie Long-Mira, Virginie Lespinet, Salomé Lalvée, Olivier Bordone, Camille Ribeyre, Virginie Tanga, Jonathan Benzaquen, Sylvie Leroy, Charlotte Cohen, Jérôme Mouroux, Charles Marquette, Marius Ilié, Paul Hofman
    Cancers.2018; 10(4): 88.     CrossRef
  • Use of the Ion AmpliSeq Cancer Hotspot Panel in clinical molecular pathology laboratories for analysis of solid tumours: With emphasis on validation with relevant single molecular pathology tests and the Oncomine Focus Assay
    Ahwon Lee, Sung-Hak Lee, Chan Kwon Jung, Gyungsin Park, Kyo Young Lee, Hyun Joo Choi, Ki Ouk Min, Tae Jung Kim, Eun Jung Lee, Youn Soo Lee
    Pathology - Research and Practice.2018; 214(5): 713.     CrossRef
  • Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor
    Jeong-Mo Bae, Jae-Kyung Won, Sung-Hye Park
    Journal of Korean Neurosurgical Society.2018; 61(3): 376.     CrossRef
  • The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics
    Caterina Fumagalli, Davide Vacirca, Alessandra Rappa, Antonio Passaro, Juliana Guarize, Paola Rafaniello Raviele, Filippo de Marinis, Lorenzo Spaggiari, Chiara Casadio, Giuseppe Viale, Massimo Barberis, Elena Guerini-Rocco
    Journal of Clinical Pathology.2018; 71(9): 767.     CrossRef
  • Clinical laboratory utilization management and improved healthcare performance
    Christopher Naugler, Deirdre L. Church
    Critical Reviews in Clinical Laboratory Sciences.2018; 55(8): 535.     CrossRef
  • Development of HLA-A, -B and -DR Typing Method Using Next-Generation Sequencing
    Dong Hee Seo, Jeong Min Lee, Mi Ok Park, Hyun Ju Lee, Seo Yoon Moon, Mijin Oh, So Young Kim, Sang-Heon Lee, Ki-Eun Hyeong, Hae-Jin Hu, Dae-Yeon Cho
    The Korean Journal of Blood Transfusion.2018; 29(3): 310.     CrossRef
  • Value-based genomics
    Jun Gong, Kathy Pan, Marwan Fakih, Sumanta Pal, Ravi Salgia
    Oncotarget.2018; 9(21): 15792.     CrossRef
Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives
Yoon Kyung Jeon, Sun Och Yoon, Jin Ho Paik, Young A Kim, Bong Kyung Shin, Hyun-Jung Kim, Hee Jeong Cha, Ji Eun Kim, Jooryung Huh, Young-Hyeh Ko
J Pathol Transl Med. 2017;51(3):224-241.   Published online May 10, 2017
DOI: https://doi.org/10.4132/jptm.2017.04.09
  • 14,429 View
  • 607 Download
  • 9 Citations
AbstractAbstract PDF
Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cell-of-origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Finally, a new perspective on the next-generation sequencing for diagnostic, prognostic, and therapeutic purpose in malignant lymphoma will be summarized.

Citations

Citations to this article as recorded by  
  • Thymus and lung mucosa-associated lymphoid tissue lymphoma with adenocarcinoma of the lung: a case report and literature review
    Yu Pang, Daosheng Li, Yiqian Chen, Qinqin Liu, Yuheng Wu, Qingliang Teng, Yuyu Liu
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • A comparison of capillary electrophoresis and next-generation sequencing in the detection of immunoglobulin heavy chain H and light chain κ gene rearrangements in the diagnosis of classic hodgkin’s lymphoma
    Juan-Juan Zhang, Yu-Xin Xie, Li-Lin Luo, Xuan-Tao Yang, Yi-Xing Wang, Yue Cao, Zheng-Bo Long, Wan-Pu Wang
    Bioengineered.2022; 13(3): 5868.     CrossRef
  • Lymphoproliferative disorder involving body fluid: diagnostic approaches and roles of ancillary studies
    Jiwon Koh, Sun Ah Shin, Ji Ae Lee, Yoon Kyung Jeon
    Journal of Pathology and Translational Medicine.2022; 56(4): 173.     CrossRef
  • Diagnostic Workup of Primary Cutaneous B Cell Lymphomas: A Clinician's Approach
    Giulia Tadiotto Cicogna, Martina Ferranti, Mauro Alaibac
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates
    Alexandra C. Hristov, Nneka I. Comfere, Claudia I. Vidal, Uma Sundram
    Journal of Cutaneous Pathology.2020; 47(11): 1103.     CrossRef
  • Primary lung mucosa-associated lymphoid tissue lymphoma accompanied by multiple sclerosis
    Ke-Ke Yu, Lei Zhu, Ji-Kai Zhao, Rui-Ying Zhao, Yu-Chen Han
    Chinese Medical Journal.2019; 132(13): 1625.     CrossRef
  • Diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma: A meta-analysis
    Woojoo Lee, Eun Shin, Bo-Hyung Kim, Hyunchul Kim, Riccardo Dolcetti
    PLOS ONE.2019; 14(11): e0225096.     CrossRef
  • Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T-cell and B-cell lymphoproliferative disorders
    Nneka Comfere, Uma Sundram, Maria Yadira Hurley, Brian Swick
    Journal of Cutaneous Pathology.2018; 45(1): 39.     CrossRef
  • A Next-Generation Sequencing Primer—How Does It Work and What Can It Do?
    Yuriy O. Alekseyev, Roghayeh Fazeli, Shi Yang, Raveen Basran, Thomas Maher, Nancy S. Miller, Daniel Remick
    Academic Pathology.2018; 5: 2374289518766521.     CrossRef
Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives
Yoon Kyung Jeon, Sun Och Yoon, Jin Ho Paik, Young A Kim, Bong Kyung Shin, Hyun-Jung Kim, Hee Jeong Cha, Ji Eun Kim, Jooryung Huh, Young-Hyeh Ko
J Pathol Transl Med. 2017;51(3):224-241.   Published online May 10, 2017
DOI: https://doi.org/10.4132/jptm.2017.04.09
  • 14,429 View
  • 607 Download
  • 9 Citations
AbstractAbstract PDF
Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cell-of-origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Finally, a new perspective on the next-generation sequencing for diagnostic, prognostic, and therapeutic purpose in malignant lymphoma will be summarized.

Citations

Citations to this article as recorded by  
  • Thymus and lung mucosa-associated lymphoid tissue lymphoma with adenocarcinoma of the lung: a case report and literature review
    Yu Pang, Daosheng Li, Yiqian Chen, Qinqin Liu, Yuheng Wu, Qingliang Teng, Yuyu Liu
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • A comparison of capillary electrophoresis and next-generation sequencing in the detection of immunoglobulin heavy chain H and light chain κ gene rearrangements in the diagnosis of classic hodgkin’s lymphoma
    Juan-Juan Zhang, Yu-Xin Xie, Li-Lin Luo, Xuan-Tao Yang, Yi-Xing Wang, Yue Cao, Zheng-Bo Long, Wan-Pu Wang
    Bioengineered.2022; 13(3): 5868.     CrossRef
  • Lymphoproliferative disorder involving body fluid: diagnostic approaches and roles of ancillary studies
    Jiwon Koh, Sun Ah Shin, Ji Ae Lee, Yoon Kyung Jeon
    Journal of Pathology and Translational Medicine.2022; 56(4): 173.     CrossRef
  • Diagnostic Workup of Primary Cutaneous B Cell Lymphomas: A Clinician's Approach
    Giulia Tadiotto Cicogna, Martina Ferranti, Mauro Alaibac
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates
    Alexandra C. Hristov, Nneka I. Comfere, Claudia I. Vidal, Uma Sundram
    Journal of Cutaneous Pathology.2020; 47(11): 1103.     CrossRef
  • Primary lung mucosa-associated lymphoid tissue lymphoma accompanied by multiple sclerosis
    Ke-Ke Yu, Lei Zhu, Ji-Kai Zhao, Rui-Ying Zhao, Yu-Chen Han
    Chinese Medical Journal.2019; 132(13): 1625.     CrossRef
  • Diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma: A meta-analysis
    Woojoo Lee, Eun Shin, Bo-Hyung Kim, Hyunchul Kim, Riccardo Dolcetti
    PLOS ONE.2019; 14(11): e0225096.     CrossRef
  • Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T-cell and B-cell lymphoproliferative disorders
    Nneka Comfere, Uma Sundram, Maria Yadira Hurley, Brian Swick
    Journal of Cutaneous Pathology.2018; 45(1): 39.     CrossRef
  • A Next-Generation Sequencing Primer—How Does It Work and What Can It Do?
    Yuriy O. Alekseyev, Roghayeh Fazeli, Shi Yang, Raveen Basran, Thomas Maher, Nancy S. Miller, Daniel Remick
    Academic Pathology.2018; 5: 2374289518766521.     CrossRef
Molecular Testing for Gastrointestinal Cancer
Hye Seung Lee, Woo Ho Kim, Yoonjin Kwak, Jiwon Koh, Jeong Mo Bae, Kyoung-Mee Kim, Mee Soo Chang, Hye Seung Han, Joon Mee Kim, Hwal Woong Kim, Hee Kyung Chang, Young Hee Choi, Ji Y. Park, Mi Jin Gu, Min Jin Lhee, Jung Yeon Kim, Hee Sung Kim, Mee-Yon Cho
J Pathol Transl Med. 2017;51(2):103-121.   Published online February 19, 2017
DOI: https://doi.org/10.4132/jptm.2017.01.24
  • 16,480 View
  • 864 Download
  • 46 Citations
AbstractAbstract PDF
With recent advances in molecular diagnostic methods and targeted cancer therapies, several molecular tests have been recommended for gastric cancer (GC) and colorectal cancer (CRC). Microsatellite instability analysis of gastrointestinal cancers is performed to screen for Lynch syndrome, predict favorable prognosis, and screen patients for immunotherapy. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has been approved in metastatic CRCs with wildtype RAS (KRAS and NRAS exon 2–4). A BRAF mutation is required for predicting poor prognosis. Additionally, amplification of human epidermal growth factor receptor 2 (HER2) and MET is also associated with resistance to EGFR inhibitor in metastatic CRC patients. The BRAF V600E mutation is found in sporadic microsatellite unstable CRCs, and thus is helpful for ruling out Lynch syndrome. In addition, the KRAS mutation is a prognostic biomarker and the PIK3CA mutation is a molecular biomarker predicting response to phosphoinositide 3-kinase/AKT/mammalian target of rapamycin inhibitors and response to aspirin therapy in CRC patients. Additionally, HER2 testing should be performed in all recurrent or metastatic GCs. If the results of HER2 immunohistochemistry are equivocal, HER2 silver or fluorescence in situ hybridization testing are essential for confirmative determination of HER2 status. Epstein-Barr virus–positive GCs have distinct characteristics, including heavy lymphoid stroma, hypermethylation phenotype, and high expression of immune modulators. Recent advances in next-generation sequencing technologies enable us to examine various genetic alterations using a single test. Pathologists play a crucial role in ensuring reliable molecular testing and they should also take an integral role between molecular laboratories and clinicians.

Citations

Citations to this article as recorded by  
  • A Standardized Pathology Report for Gastric Cancer: 2nd Edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Gastric Cancer.2023; 23(1): 107.     CrossRef
  • A standardized pathology report for gastric cancer: 2nd edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Pathology and Translational Medicine.2023; 57(1): 1.     CrossRef
  • Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
    Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
    Journal of Gastric Cancer.2023; 23(1): 3.     CrossRef
  • Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis
    Jina Choi, Nayoung Kim, Ryoung Hee Nam, Jin Won Kim, Chin-Hee Song, Hee Young Na, Gyeong Hoon Kang, Alvaro Galli
    PLOS ONE.2023; 18(2): e0282017.     CrossRef
  • Exosomal circ_0001190 Regulates the Progression of Gastric Cancer via miR-586/SOSTDC1 Axis
    Chao Liu, Jing Yang, Fengchi Zhu, Zhiying Zhao, Lixue Gao
    Biochemical Genetics.2022; 60(6): 1895.     CrossRef
  • Optimization of pre‐analytical and analytical steps for DNA and RNA analysis of fresh cytology samples
    Ana Dolinar, Gašper Grubelnik, Irena Srebotnik‐Kirbiš, Margareta Strojan Fležar, Margareta Žlajpah
    Cancer Medicine.2022; 11(21): 4021.     CrossRef
  • Connexin 43 upregulation by dioscin‐inhibited gastric cancer metastasis by suppressing PI3K /Akt pathway
    Yu Kou, Rentao Zhu, Qidi Sun, Zhuoqun Li, Xuan Feng, Hairong Xu
    Food Science & Nutrition.2022;[Epub]     CrossRef
  • Molecular Pathology of Gastric Cancer
    Moonsik Kim, An Na Seo
    Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
  • Case report: Undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy
    Jiaying Liu, Xiaona Chang, Guixiang Xiao, Jingmin Zhong, Bo Huang, Jiwei Zhang, Beibei Gao, Gang Peng, Xiu Nie
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The SUMO E3 ligase CBX4 is identified as a poor prognostic marker of gastric cancer through multipronged OMIC analyses
    Yi Pan, Qingshang Li, Zhijun Cao, Shuliang Zhao
    Genes & Diseases.2021; 8(6): 827.     CrossRef
  • Worldwide variation in lynch syndrome screening: case for universal screening in low colorectal cancer prevalence areas
    George Kunnackal John, Vipin Das Villgran, Christine Caufield-Noll, Francis Giardiello
    Familial Cancer.2021; 20(2): 145.     CrossRef
  • Tamoxifen Downregulates the Expression of Notch1 and DLL1 Genes in MKN-45 Gastric Cancer Cells
    Faranak Khanipouyani, Hassan Akrami
    Journal of Gastrointestinal Cancer.2021; 52(3): 922.     CrossRef
  • Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis
    Saeranee Siriphak, Ravinnipa Chanakankun, Tanakorn Proungvitaya, Sittiruk Roytrakul, Doungdean Tummanatsakun, Wunchana Seubwai, Molin Wongwattanakul, Siriporn Proungvitaya
    Molecules.2021; 26(11): 3105.     CrossRef
  • ISH-based HER2 diagnostics
    Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, Oliver Stoss
    Der Pathologe.2021; 42(S1): 62.     CrossRef
  • Identification and Analysis of Key Genes Driving Gastric Cancer Through Bioinformatics
    Zhao Liu, Shihai Liu, Jing Guo, Libin Sun, Shasha Wang, Yixuan Wang, Wensheng Qiu, Jing Lv
    Genetic Testing and Molecular Biomarkers.2021; 25(1): 1.     CrossRef
  • Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker
    Francis Yew Fu Tieng, Nadiah Abu, Learn-Han Lee, Nurul-Syakima Ab Mutalib
    Diagnostics.2021; 11(3): 544.     CrossRef
  • Metformin attenuates synergic effect of diabetes mellitus and Helicobacter pylori infection on gastric cancer cells proliferation by suppressing PTEN expression
    Huibin Lu, Xinwei Han, Jianzhuang Ren, Kewei Ren, Zongming Li, Quanhui Zhang
    Journal of Cellular and Molecular Medicine.2021; 25(10): 4534.     CrossRef
  • Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review
    Zhi-da Chen, Peng-fei Zhang, Hong-qing Xi, Bo Wei, Lin Chen, Yun Tang
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Tumor immune response and immunotherapy in gastric cancer
    Yoonjin Kwak, An Na Seo, Hee Eun Lee, Hye Seung Lee
    Journal of Pathology and Translational Medicine.2020; 54(1): 20.     CrossRef
  • Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR
    Boram Kim, Soo Kyung Nam, Soo Hyun Seo, Kyoung Un Park, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer
    Yoonjin Kwak, Jiwon Koh, Yujun Park, Yun Ji Hong, Kyoung Un Park, Hyung-Ho Kim, Do Joong Park, Sang-Hoon Ahn, Woo Ho Kim, Hye Seung Lee
    British Journal of Cancer.2020; 122(9): 1399.     CrossRef
  • High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies
    Amanda Bortolini Silveira, François-Clément Bidard, Amélie Kasperek, Samia Melaabi, Marie-Laure Tanguy, Manuel Rodrigues, Guillaume Bataillon, Luc Cabel, Bruno Buecher, Jean-Yves Pierga, Charlotte Proudhon, Marc-Henri Stern
    Clinical Chemistry.2020; 66(4): 606.     CrossRef
  • Chitosan: A compound for drug delivery system in gastric cancer-a review
    Rana Shafabakhsh, Bahman Yousefi, Zatollah Asemi, Banafsheh Nikfar, Mohammad Ali Mansournia, Jamal Hallajzadeh
    Carbohydrate Polymers.2020; 242: 116403.     CrossRef
  • MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
    Maria Grazia Rodriquenz, Giandomenico Roviello, Alberto D’Angelo, Daniele Lavacchi, Franco Roviello, Karol Polom
    Journal of Clinical Medicine.2020; 9(5): 1427.     CrossRef
  • Theoretical calculations of molecular descriptors for anticancer activities of 1, 2, 3-triazole-pyrimidine derivatives against gastric cancer cell line (MGC-803): DFT, QSAR and docking approaches
    Rhoda Oyeladun Oyewole, Abel Kolawole Oyebamiji, Banjo Semire
    Heliyon.2020; 6(5): e03926.     CrossRef
  • Identification of a Clinical Cutoff Value for Multiplex KRASG12/G13 Mutation Detection in Colorectal Adenocarcinoma Patients Using Digital Droplet PCR, and Comparison with Sanger Sequencing and PNA Clamping Assay
    Kyung Ha Lee, Tae Hee Lee, Min Kyung Choi, In Sun Kwon, Go Eun Bae, Min-Kyung Yeo
    Journal of Clinical Medicine.2020; 9(7): 2283.     CrossRef
  • PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
    Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Keun-Wook Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee
    Cancer Research and Treatment.2020; 52(3): 661.     CrossRef
  • Clinical and Molecular Assessment of Patients with Lynch Syndrome and Sarcomas Underpinning the Association with MSH2 Germline Pathogenic Variants
    Nathália de Angelis de Carvalho, Bianca Naomi Niitsuma, Vanessa Nascimento Kozak, Felipe D’almeida Costa, Mariana Petaccia de Macedo, Bruna Elisa Catin Kupper, Maria Letícia Gobo Silva, Maria Nirvana Formiga, Sahlua Miguel Volc, Samuel Aguiar Junior, Eden
    Cancers.2020; 12(7): 1848.     CrossRef
  • Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis
    Junhui Yu, Shan Li, Jing Guo, Zhengshui Xu, Jianbao Zheng, Xuejun Sun
    Cell Death & Disease.2020;[Epub]     CrossRef
  • YAP promotes self-renewal of gastric cancer cells by inhibiting expression of L-PTGDS and PTGDR2
    Qingli Bie, Xiaozhe Li, Shiqi Liu, Xiao Yang, Zhenwen Qian, Rou Zhao, Xiaobei Zhang, Bin Zhang
    International Journal of Clinical Oncology.2020; 25(12): 2055.     CrossRef
  • ISH-basierte HER2-Diagnostik
    Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, Oliver Stoss
    Der Pathologe.2020; 41(6): 606.     CrossRef
  • Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
    Xinli An, Zekun Wei, Botian Ran, Hao Tian, Hongyu Gu, Yan Liu, Hongjuan Cui, Shunqin Zhu
    Anti-Cancer Agents in Medicinal Chemistry.2020; 20(17): 2114.     CrossRef
  • Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
    Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo
    Gastrointestinal Disorders.2020; 3(1): 1.     CrossRef
  • Next-generation Sequencing in the Management of Gastric and Esophageal Cancers
    Jill C. Rubinstein, Norman G. Nicolson, Nita Ahuja
    Surgical Clinics of North America.2019; 99(3): 511.     CrossRef
  • Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy
    Tania Fleitas-Kanonnikoff, Carolina Martinez‐Ciarpaglini, Josefina Ayala, Cinthia Gauna, Rita Denis, Ita Yoffe, Silvia Sforza, María Teresa Martínez, Alicia Pomata, Maider Ibarrola‐Villava, Sipan Arevshatyan, Verónica Burriel, Diego Boscá, Oscar Pastor, A
    Cancer Medicine.2019; 8(6): 3120.     CrossRef
  • Human epidermal growth factor receptor 2-positive digestive tumors
    Anna D. Wagner, Berna C. Özdemir, Josef Rüschoff
    Current Opinion in Oncology.2019; 31(4): 354.     CrossRef
  • Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications
    Carolina Martinez-Ciarpaglini, Tania Fleitas-Kanonnikoff, Valentina Gambardella, Marta Llorca, Cristina Mongort, Regina Mengual, Gema Nieto, Lara Navarro, Marisol Huerta, Susana Rosello, Desamparados Roda, Noelia Tarazona, Samuel Navarro, Gloria Ribas, An
    ESMO Open.2019; 4(3): e000470.     CrossRef
  • Current and future molecular diagnostics of gastric cancer
    Rachel Sin-Yu Choi, Wing Yin Xenia Lai, Lok Ting Claire Lee, Wing Lam Christa Wong, Xiao Meng Pei, Hin Fung Tsang, Joel Johnson Leung, William Chi Shing Cho, Man Kee Maggie Chu, Elaine Yue Ling Wong, Sze Chuen Cesar Wong
    Expert Review of Molecular Diagnostics.2019; 19(10): 863.     CrossRef
  • Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer
    Yujun Park, Jiwon Koh, Yoonjin Kwak, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
    Cancer Immunology, Immunotherapy.2019; 68(11): 1779.     CrossRef
  • Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications
    Jiwon Koh, Keun-Wook Lee, Soo Kyung Nam, An Na Seo, Ji-Won Kim, Jin Won Kim, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
    The Oncologist.2019; 24(12): e1321.     CrossRef
  • Mechanisms and Therapy for Cancer Metastasis to the Brain
    Federica Franchino, Roberta Rudà, Riccardo Soffietti
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Status of programmed death-ligand 1 expression in sarcomas
    Hyung Kyu Park, Mingi Kim, Minjung Sung, Seung Eun Lee, Yu Jin Kim, Yoon-La Choi
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • Design and synthesis of near-infrared fluorescence-enhancement probes for the cancer-specific enzyme hNQO1
    Changyu Zhang, Bei-Bei Zhai, Tao Peng, Zelin Zhong, Lianbin Xu, Qiang-Zhe Zhang, Lu-Yuan Li, Long Yi, Zhen Xi
    Dyes and Pigments.2017; 143: 245.     CrossRef
  • Progress in the treatment of advanced gastric cancer
    Zheyu Song, Yuanyu Wu, Jiebing Yang, Dingquan Yang, Xuedong Fang
    Tumor Biology.2017; 39(7): 101042831771462.     CrossRef
  • Pathologische Einteilung und Diagnostik des Ösophagus- und Magenkarzinoms
    S. Förster, A. Tannapfel
    Der Gastroenterologe.2017; 12(5): 394.     CrossRef
  • NR4A1-induced increase in the sensitivity of a human gastric cancer line to TNFα-mediated apoptosis is associated with the inhibition of JNK/Parkin-dependent mitophagy
    Hongzhu Yan, Feng Xiao, Jue Zou, Chengmin Qiu, Weiwei Sun, Minmin Gu, Li Zhang
    International Journal of Oncology.2017;[Epub]     CrossRef
Molecular Testing for Gastrointestinal Cancer
Hye Seung Lee, Woo Ho Kim, Yoonjin Kwak, Jiwon Koh, Jeong Mo Bae, Kyoung-Mee Kim, Mee Soo Chang, Hye Seung Han, Joon Mee Kim, Hwal Woong Kim, Hee Kyung Chang, Young Hee Choi, Ji Y. Park, Mi Jin Gu, Min Jin Lhee, Jung Yeon Kim, Hee Sung Kim, Mee-Yon Cho
J Pathol Transl Med. 2017;51(2):103-121.   Published online February 19, 2017
DOI: https://doi.org/10.4132/jptm.2017.01.24
  • 16,480 View
  • 864 Download
  • 46 Citations
AbstractAbstract PDF
With recent advances in molecular diagnostic methods and targeted cancer therapies, several molecular tests have been recommended for gastric cancer (GC) and colorectal cancer (CRC). Microsatellite instability analysis of gastrointestinal cancers is performed to screen for Lynch syndrome, predict favorable prognosis, and screen patients for immunotherapy. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has been approved in metastatic CRCs with wildtype RAS (KRAS and NRAS exon 2–4). A BRAF mutation is required for predicting poor prognosis. Additionally, amplification of human epidermal growth factor receptor 2 (HER2) and MET is also associated with resistance to EGFR inhibitor in metastatic CRC patients. The BRAF V600E mutation is found in sporadic microsatellite unstable CRCs, and thus is helpful for ruling out Lynch syndrome. In addition, the KRAS mutation is a prognostic biomarker and the PIK3CA mutation is a molecular biomarker predicting response to phosphoinositide 3-kinase/AKT/mammalian target of rapamycin inhibitors and response to aspirin therapy in CRC patients. Additionally, HER2 testing should be performed in all recurrent or metastatic GCs. If the results of HER2 immunohistochemistry are equivocal, HER2 silver or fluorescence in situ hybridization testing are essential for confirmative determination of HER2 status. Epstein-Barr virus–positive GCs have distinct characteristics, including heavy lymphoid stroma, hypermethylation phenotype, and high expression of immune modulators. Recent advances in next-generation sequencing technologies enable us to examine various genetic alterations using a single test. Pathologists play a crucial role in ensuring reliable molecular testing and they should also take an integral role between molecular laboratories and clinicians.

Citations

Citations to this article as recorded by  
  • A Standardized Pathology Report for Gastric Cancer: 2nd Edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Gastric Cancer.2023; 23(1): 107.     CrossRef
  • A standardized pathology report for gastric cancer: 2nd edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Pathology and Translational Medicine.2023; 57(1): 1.     CrossRef
  • Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
    Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
    Journal of Gastric Cancer.2023; 23(1): 3.     CrossRef
  • Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis
    Jina Choi, Nayoung Kim, Ryoung Hee Nam, Jin Won Kim, Chin-Hee Song, Hee Young Na, Gyeong Hoon Kang, Alvaro Galli
    PLOS ONE.2023; 18(2): e0282017.     CrossRef
  • Exosomal circ_0001190 Regulates the Progression of Gastric Cancer via miR-586/SOSTDC1 Axis
    Chao Liu, Jing Yang, Fengchi Zhu, Zhiying Zhao, Lixue Gao
    Biochemical Genetics.2022; 60(6): 1895.     CrossRef
  • Optimization of pre‐analytical and analytical steps for DNA and RNA analysis of fresh cytology samples
    Ana Dolinar, Gašper Grubelnik, Irena Srebotnik‐Kirbiš, Margareta Strojan Fležar, Margareta Žlajpah
    Cancer Medicine.2022; 11(21): 4021.     CrossRef
  • Connexin 43 upregulation by dioscin‐inhibited gastric cancer metastasis by suppressing PI3K /Akt pathway
    Yu Kou, Rentao Zhu, Qidi Sun, Zhuoqun Li, Xuan Feng, Hairong Xu
    Food Science & Nutrition.2022;[Epub]     CrossRef
  • Molecular Pathology of Gastric Cancer
    Moonsik Kim, An Na Seo
    Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
  • Case report: Undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy
    Jiaying Liu, Xiaona Chang, Guixiang Xiao, Jingmin Zhong, Bo Huang, Jiwei Zhang, Beibei Gao, Gang Peng, Xiu Nie
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The SUMO E3 ligase CBX4 is identified as a poor prognostic marker of gastric cancer through multipronged OMIC analyses
    Yi Pan, Qingshang Li, Zhijun Cao, Shuliang Zhao
    Genes & Diseases.2021; 8(6): 827.     CrossRef
  • Worldwide variation in lynch syndrome screening: case for universal screening in low colorectal cancer prevalence areas
    George Kunnackal John, Vipin Das Villgran, Christine Caufield-Noll, Francis Giardiello
    Familial Cancer.2021; 20(2): 145.     CrossRef
  • Tamoxifen Downregulates the Expression of Notch1 and DLL1 Genes in MKN-45 Gastric Cancer Cells
    Faranak Khanipouyani, Hassan Akrami
    Journal of Gastrointestinal Cancer.2021; 52(3): 922.     CrossRef
  • Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis
    Saeranee Siriphak, Ravinnipa Chanakankun, Tanakorn Proungvitaya, Sittiruk Roytrakul, Doungdean Tummanatsakun, Wunchana Seubwai, Molin Wongwattanakul, Siriporn Proungvitaya
    Molecules.2021; 26(11): 3105.     CrossRef
  • ISH-based HER2 diagnostics
    Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, Oliver Stoss
    Der Pathologe.2021; 42(S1): 62.     CrossRef
  • Identification and Analysis of Key Genes Driving Gastric Cancer Through Bioinformatics
    Zhao Liu, Shihai Liu, Jing Guo, Libin Sun, Shasha Wang, Yixuan Wang, Wensheng Qiu, Jing Lv
    Genetic Testing and Molecular Biomarkers.2021; 25(1): 1.     CrossRef
  • Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker
    Francis Yew Fu Tieng, Nadiah Abu, Learn-Han Lee, Nurul-Syakima Ab Mutalib
    Diagnostics.2021; 11(3): 544.     CrossRef
  • Metformin attenuates synergic effect of diabetes mellitus and Helicobacter pylori infection on gastric cancer cells proliferation by suppressing PTEN expression
    Huibin Lu, Xinwei Han, Jianzhuang Ren, Kewei Ren, Zongming Li, Quanhui Zhang
    Journal of Cellular and Molecular Medicine.2021; 25(10): 4534.     CrossRef
  • Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review
    Zhi-da Chen, Peng-fei Zhang, Hong-qing Xi, Bo Wei, Lin Chen, Yun Tang
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Tumor immune response and immunotherapy in gastric cancer
    Yoonjin Kwak, An Na Seo, Hee Eun Lee, Hye Seung Lee
    Journal of Pathology and Translational Medicine.2020; 54(1): 20.     CrossRef
  • Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR
    Boram Kim, Soo Kyung Nam, Soo Hyun Seo, Kyoung Un Park, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer
    Yoonjin Kwak, Jiwon Koh, Yujun Park, Yun Ji Hong, Kyoung Un Park, Hyung-Ho Kim, Do Joong Park, Sang-Hoon Ahn, Woo Ho Kim, Hye Seung Lee
    British Journal of Cancer.2020; 122(9): 1399.     CrossRef
  • High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies
    Amanda Bortolini Silveira, François-Clément Bidard, Amélie Kasperek, Samia Melaabi, Marie-Laure Tanguy, Manuel Rodrigues, Guillaume Bataillon, Luc Cabel, Bruno Buecher, Jean-Yves Pierga, Charlotte Proudhon, Marc-Henri Stern
    Clinical Chemistry.2020; 66(4): 606.     CrossRef
  • Chitosan: A compound for drug delivery system in gastric cancer-a review
    Rana Shafabakhsh, Bahman Yousefi, Zatollah Asemi, Banafsheh Nikfar, Mohammad Ali Mansournia, Jamal Hallajzadeh
    Carbohydrate Polymers.2020; 242: 116403.     CrossRef
  • MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
    Maria Grazia Rodriquenz, Giandomenico Roviello, Alberto D’Angelo, Daniele Lavacchi, Franco Roviello, Karol Polom
    Journal of Clinical Medicine.2020; 9(5): 1427.     CrossRef
  • Theoretical calculations of molecular descriptors for anticancer activities of 1, 2, 3-triazole-pyrimidine derivatives against gastric cancer cell line (MGC-803): DFT, QSAR and docking approaches
    Rhoda Oyeladun Oyewole, Abel Kolawole Oyebamiji, Banjo Semire
    Heliyon.2020; 6(5): e03926.     CrossRef
  • Identification of a Clinical Cutoff Value for Multiplex KRASG12/G13 Mutation Detection in Colorectal Adenocarcinoma Patients Using Digital Droplet PCR, and Comparison with Sanger Sequencing and PNA Clamping Assay
    Kyung Ha Lee, Tae Hee Lee, Min Kyung Choi, In Sun Kwon, Go Eun Bae, Min-Kyung Yeo
    Journal of Clinical Medicine.2020; 9(7): 2283.     CrossRef
  • PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
    Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Keun-Wook Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee
    Cancer Research and Treatment.2020; 52(3): 661.     CrossRef
  • Clinical and Molecular Assessment of Patients with Lynch Syndrome and Sarcomas Underpinning the Association with MSH2 Germline Pathogenic Variants
    Nathália de Angelis de Carvalho, Bianca Naomi Niitsuma, Vanessa Nascimento Kozak, Felipe D’almeida Costa, Mariana Petaccia de Macedo, Bruna Elisa Catin Kupper, Maria Letícia Gobo Silva, Maria Nirvana Formiga, Sahlua Miguel Volc, Samuel Aguiar Junior, Eden
    Cancers.2020; 12(7): 1848.     CrossRef
  • Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis
    Junhui Yu, Shan Li, Jing Guo, Zhengshui Xu, Jianbao Zheng, Xuejun Sun
    Cell Death & Disease.2020;[Epub]     CrossRef
  • YAP promotes self-renewal of gastric cancer cells by inhibiting expression of L-PTGDS and PTGDR2
    Qingli Bie, Xiaozhe Li, Shiqi Liu, Xiao Yang, Zhenwen Qian, Rou Zhao, Xiaobei Zhang, Bin Zhang
    International Journal of Clinical Oncology.2020; 25(12): 2055.     CrossRef
  • ISH-basierte HER2-Diagnostik
    Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, Oliver Stoss
    Der Pathologe.2020; 41(6): 606.     CrossRef
  • Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
    Xinli An, Zekun Wei, Botian Ran, Hao Tian, Hongyu Gu, Yan Liu, Hongjuan Cui, Shunqin Zhu
    Anti-Cancer Agents in Medicinal Chemistry.2020; 20(17): 2114.     CrossRef
  • Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
    Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo
    Gastrointestinal Disorders.2020; 3(1): 1.     CrossRef
  • Next-generation Sequencing in the Management of Gastric and Esophageal Cancers
    Jill C. Rubinstein, Norman G. Nicolson, Nita Ahuja
    Surgical Clinics of North America.2019; 99(3): 511.     CrossRef
  • Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy
    Tania Fleitas-Kanonnikoff, Carolina Martinez‐Ciarpaglini, Josefina Ayala, Cinthia Gauna, Rita Denis, Ita Yoffe, Silvia Sforza, María Teresa Martínez, Alicia Pomata, Maider Ibarrola‐Villava, Sipan Arevshatyan, Verónica Burriel, Diego Boscá, Oscar Pastor, A
    Cancer Medicine.2019; 8(6): 3120.     CrossRef
  • Human epidermal growth factor receptor 2-positive digestive tumors
    Anna D. Wagner, Berna C. Özdemir, Josef Rüschoff
    Current Opinion in Oncology.2019; 31(4): 354.     CrossRef
  • Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications
    Carolina Martinez-Ciarpaglini, Tania Fleitas-Kanonnikoff, Valentina Gambardella, Marta Llorca, Cristina Mongort, Regina Mengual, Gema Nieto, Lara Navarro, Marisol Huerta, Susana Rosello, Desamparados Roda, Noelia Tarazona, Samuel Navarro, Gloria Ribas, An
    ESMO Open.2019; 4(3): e000470.     CrossRef
  • Current and future molecular diagnostics of gastric cancer
    Rachel Sin-Yu Choi, Wing Yin Xenia Lai, Lok Ting Claire Lee, Wing Lam Christa Wong, Xiao Meng Pei, Hin Fung Tsang, Joel Johnson Leung, William Chi Shing Cho, Man Kee Maggie Chu, Elaine Yue Ling Wong, Sze Chuen Cesar Wong
    Expert Review of Molecular Diagnostics.2019; 19(10): 863.     CrossRef
  • Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer
    Yujun Park, Jiwon Koh, Yoonjin Kwak, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
    Cancer Immunology, Immunotherapy.2019; 68(11): 1779.     CrossRef
  • Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications
    Jiwon Koh, Keun-Wook Lee, Soo Kyung Nam, An Na Seo, Ji-Won Kim, Jin Won Kim, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
    The Oncologist.2019; 24(12): e1321.     CrossRef
  • Mechanisms and Therapy for Cancer Metastasis to the Brain
    Federica Franchino, Roberta Rudà, Riccardo Soffietti
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Status of programmed death-ligand 1 expression in sarcomas
    Hyung Kyu Park, Mingi Kim, Minjung Sung, Seung Eun Lee, Yu Jin Kim, Yoon-La Choi
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • Design and synthesis of near-infrared fluorescence-enhancement probes for the cancer-specific enzyme hNQO1
    Changyu Zhang, Bei-Bei Zhai, Tao Peng, Zelin Zhong, Lianbin Xu, Qiang-Zhe Zhang, Lu-Yuan Li, Long Yi, Zhen Xi
    Dyes and Pigments.2017; 143: 245.     CrossRef
  • Progress in the treatment of advanced gastric cancer
    Zheyu Song, Yuanyu Wu, Jiebing Yang, Dingquan Yang, Xuedong Fang
    Tumor Biology.2017; 39(7): 101042831771462.     CrossRef
  • Pathologische Einteilung und Diagnostik des Ösophagus- und Magenkarzinoms
    S. Förster, A. Tannapfel
    Der Gastroenterologe.2017; 12(5): 394.     CrossRef
  • NR4A1-induced increase in the sensitivity of a human gastric cancer line to TNFα-mediated apoptosis is associated with the inhibition of JNK/Parkin-dependent mitophagy
    Hongzhu Yan, Feng Xiao, Jue Zou, Chengmin Qiu, Weiwei Sun, Minmin Gu, Li Zhang
    International Journal of Oncology.2017;[Epub]     CrossRef
Characteristics of Cutaneous Lymphomas in Korea According to the New WHO-EORTC Classification: Report of a Nationwide Study
Jae Ho Han, Young-Hyeh Ko, Yun Kyung Kang, Wan-Seop Kim, Yoon Jung Kim, Insun Kim, Hyun-Jung Kim, Soo Kee Min, Chan-Kum Park, Chan-Sik Park, Bong-Kyung Shin, Woo Ick Yang, Young-Ha Oh, Jong Sil Lee, Juhie Lee, Tae Hui Lee, Hyekyung Lee, Ho Jung Lee, Yoon Kyung Jeon, Hee Jeong Cha, Yoo-Duk Choi, Chul Woo Kim
Korean J Pathol. 2014;48(2):126-132.   Published online April 28, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.2.126
  • 7,375 View
  • 77 Download
  • 11 Citations
AbstractAbstract PDF
Background

Previously, cutaneous lymphomas were classified according to either the European Organization for the Research and Treatment of Cancer (EORTC) or the World Health Organization (WHO) classification paradigms. The aim of this study was to determine the relative frequency of Korean cutaneous lymphoma according to the new WHO-EORTC classification system.

Methods

A total of 517 patients were recruited during a recent 5 year-period (2006-2010) from 21 institutes and classified according to the WHO-EORTC criteria.

Results

The patients included 298 males and 219 females, and the mean age at diagnosis was 49 years. The lesions preferentially affected the trunk area (40.2%). The most frequent subtypes in order of decreasing prevalence were mycosis fungoides (22.2%), peripheral T-cell lymphoma (17.2%), CD30+ T-cell lymphoproliferative disorder (13.7%), and extranodal natural killer/T (NK/T) cell lymphoma, nasal type (12.0%). Diffuse large B-cell lymphoma accounted for 11.2% of cases, half of which were secondary cutaneous involvement; other types of B-cell lymphoma accounted for less than 1% of cases.

Conclusions

In comparison with data from Western countries, this study revealed relatively lower rates of mycosis fungoides and B-cell lymphoma in Korean patients, as well as higher rates of subcutaneous panniculitis-like T-cell lymphoma and NK/T cell lymphoma.

Citations

Citations to this article as recorded by  
  • The First Case of Acute Myeloid Leukemia With t(10;11)(p13;q21);PICALM-MLLT10 Rearrangement Presenting With Extensive Skin Involvement
    Min-Seung Park, Hyun-Young Kim, Jae Joon Lee, Duck Cho, Chul Won Jung, Hee-Jin Kim, Sun-Hee Kim
    Annals of Laboratory Medicine.2023; 43(3): 310.     CrossRef
  • Recent advances on cutaneous lymphoma epidemiology
    G. Dobos, M. Miladi, L. Michel, C. Ram-Wolff, M. Battistella, M. Bagot, A. de Masson
    La Presse Médicale.2022; 51(1): 104108.     CrossRef
  • Specific cutaneous infiltrates in patients with haematological neoplasms: a retrospective study with 49 patients
    Rebeca Calado, Maria Relvas, Francisca Morgado, José Carlos Cardoso, Oscar Tellechea
    Australasian Journal of Dermatology.2021;[Epub]     CrossRef
  • Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients
    Gabor Dobos, Anne Pohrt, Caroline Ram-Wolff, Céleste Lebbé, Jean-David Bouaziz, Maxime Battistella, Martine Bagot, Adèle de Masson
    Cancers.2020; 12(10): 2921.     CrossRef
  • Primary cutaneous lymphoma in Argentina: a report of a nationwide study of 416 patients
    Alejandra Abeldaño, Paula Enz, Matias Maskin, Andrea B. Cervini, Natallia Torres, Ana C. Acosta, Marina Narbaitz, Silvia Vanzulli, Mirta Orentrajch, Marta A. Villareal, Maria L. Garcia Pazos, Mariana Arias, Evelyn A. Zambrano Franco, Maria I. Fontana, Rob
    International Journal of Dermatology.2019; 58(4): 449.     CrossRef
  • Post-thymic CD4 positive cytotoxic T cell infiltrates of the skin: A clinical and histomorphologic spectrum of the unique CD4 positive T cell of immunosenescence
    Cynthia M. Magro, Luke C. Olson, Shabnam Momtahen
    Annals of Diagnostic Pathology.2019; 38: 99.     CrossRef
  • Cutaneous lymphomas in Taiwan: A review of 118 cases from a medical center in southern Taiwan
    Chaw-Ning Lee, Chao-Kai Hsu, Kung-Chao Chang, Cheng-Lin Wu, Tsai-Yun Chen, Julia Yu-Yun Lee
    Dermatologica Sinica.2018; 36(1): 16.     CrossRef
  • Imaging analysis of superficial soft tissue lymphomas
    In Sook Lee, You Seon Song, Seung Hyun Lee, Young Jin Choi, Sung Moon Lee
    Clinical Imaging.2018; 49: 111.     CrossRef
  • Epidemiologic, clinical and demographic features of primary cutaneous lymphomas in Castilla-La Mancha, Spain: are we different?
    C. Ramos-Rodríguez, M. García-Rojo, G. Romero-Aguilera, M. García-Arpa, L. González-López, M.P. Sánchez-Caminero, J. González-García, M. Delgado-Portela, M.P. Cortina-De La Calle, M.F. Relea-Calatayud, F. Martín-Dávila, R. López-Pérez, M. Ramos-Rodríguez
    Journal of the European Academy of Dermatology and Venereology.2018; 32(5): e168.     CrossRef
  • Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior
    Mineui Hong, Taehee Lee, So Young Kang, Suk-Jin Kim, Wonseog Kim, Young-Hyeh Ko
    Modern Pathology.2016; 29(5): 430.     CrossRef
  • Cutaneous lymphoma: Kids are not just little people
    Katalin Ferenczi, Hanspaul S. Makkar
    Clinics in Dermatology.2016; 34(6): 749.     CrossRef
Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group
Hyojin Kim, Hyo Sup Shim, Lucia Kim, Tae-Jung Kim, Kun Young Kwon, Geon Kook Lee, Jin-Haeng Chung
Korean J Pathol. 2014;48(1):1-9.   Published online February 25, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.1.1
  • 11,510 View
  • 106 Download
  • 19 Citations
AbstractAbstract PDF

Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor. However, the prevalence of the ALK fusion is low, so accurate patient identification is crucial for successful treatment using ALK inhibitors. Furthermore, most patients with lung cancer present with advanced-stage disease at the time of diagnosis, so it is important for pathologists to detect ALK-rearranged patients while effectively maximizing small biopsy or cytology specimens. In this review, we propose a guideline recommendation for ALK testing approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by  
  • Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
    Gabriele Gamerith, Marcel Kloppenburg, Finn Mildner, Arno Amann, Sabine Merkelbach-Bruse, Carina Heydt, Janna Siemanowski, Reinhard Buettner, Michael Fiegl, Claudia Manzl, Georg Pall
    Cancers.2022; 14(20): 5113.     CrossRef
  • ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights
    Minsun Jung, Kyung Chul Moon, Jeongmo Bae, Tae Min Kim, Miso Kim, Yoon Kyung Jeon, Cheol Lee
    Archives of Pathology & Laboratory Medicine.2022; 146(12): 1460.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
    Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
    Lung Cancer.2019; 136: 65.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H. Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benj
    Journal of Thoracic Oncology.2018; 13(3): 323.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H. Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benj
    The Journal of Molecular Diagnostics.2018; 20(2): 129.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benja
    Archives of Pathology & Laboratory Medicine.2018; 142(3): 321.     CrossRef
  • 5′/ 3′ imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer
    Yongqing Tong, Zhijun Zhao, Bei Liu, Anyu Bao, Hongyun Zheng, Jian Gu, Mary McGrath, Ying Xia, Bihua Tan, Chunhua Song, Yan Li
    Journal of Experimental & Clinical Cancer Research.2018;[Epub]     CrossRef
  • Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study
    Dae Ho Lee, Ming-Sound Tsao, Karl-Otto Kambartel, Hiroshi Isobe, Ming-Shyan Huang, Carlos H. Barrios, Adnan Khattak, Filippo de Marinis, Smita Kothari, Ashwini Arunachalam, Xiting Cao, Thomas Burke, Amparo Valladares, Javier de Castro, Aamir Ahmad
    PLOS ONE.2018; 13(8): e0202865.     CrossRef
  • Microfluidics-based immunofluorescence for fast staining of ALK in lung adenocarcinoma
    Saška Brajkovic, Benjamin Pelz, Maria-Giuseppina Procopio, Anne-Laure Leblond, Grégoire Repond, Ariane Schaub-Clerigué, Diego G Dupouy, Alex Soltermann
    Diagnostic Pathology.2018;[Epub]     CrossRef
  • Expanded Circulating Tumor Cells from a Patient with ALK- Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study
    Zhuo Zhang, Hiroe Shiratsuchi, Nallasivam Palanisamy, Sunitha Nagrath, Nithya Ramnath
    Journal of Thoracic Oncology.2017; 12(2): 397.     CrossRef
  • Molecular Testing of Lung Cancers
    Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
    Journal of Pathology and Translational Medicine.2017; 51(3): 242.     CrossRef
  • Novel ALK fusion partners in lung cancer
    Aglaya G. Iyevleva, Grigory A. Raskin, Vladislav I. Tiurin, Anna P. Sokolenko, Natalia V. Mitiushkina, Svetlana N. Aleksakhina, Aigul R. Garifullina, Tatiana N. Strelkova, Valery O. Merkulov, Alexandr O. Ivantsov, Ekatherina Sh. Kuligina, Kazimir M. Pozha
    Cancer Letters.2015; 362(1): 116.     CrossRef
  • Strategic management of transthoracic needle aspirates for histological subtyping andEGFRtesting in patients with peripheral lung cancer: An institutional experience
    Choonhee Son, Eun-Ju Kang, Mee Sook Roh
    Diagnostic Cytopathology.2015; 43(7): 532.     CrossRef
  • Current and future molecular diagnostics in non-small-cell lung cancer
    Chun Man Li, Wing Ying Chu, Di Lun Wong, Hin Fung Tsang, Nancy Bo Yin Tsui, Charles Ming Lok Chan, Vivian Wei Wen Xue, Parco Ming Fai Siu, Benjamin Yat Ming Yung, Lawrence Wing Chi Chan, Sze Chuen Cesar Wong
    Expert Review of Molecular Diagnostics.2015; 15(8): 1061.     CrossRef
  • Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma
    Haeryoung Kim, Young Nyun Park
    Best Practice & Research Clinical Gastroenterology.2014; 28(5): 813.     CrossRef
  • Molecular Pathology of Lung Cancer: Current Status and Future Directions
    Mee Sook Roh
    Tuberculosis and Respiratory Diseases.2014; 77(2): 49.     CrossRef
  • Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity
    Sung-Jun Ko, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Jin-Haeng Chung, Tae Jung Kim, Kyung Won Lee, Kwhanmien Kim, Sanghoon Jheon, Hyojin Kim, Jae Ho Lee, Choon-Taek Lee
    BMC Cancer.2014;[Epub]     CrossRef
Proposal for a Standardized Pathology Report of Gastroenteropancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
Mee-Yon Cho, Jin Hee Sohn, So Young Jin, Hyunki Kim, Eun Sun Jung, Mi-Jung Kim, Kyoung-Mee Kim, Woo Ho Kim, Joon Mee Kim, Yun Kyung Kang, Joon Hyuk Choi, Dae Young Kang, Youn Wha Kim, Eun Hee Choi
Korean J Pathol. 2013;47(3):227-237.   Published online June 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.3.227
  • 12,404 View
  • 136 Download
  • 12 Citations
AbstractAbstract PDF
Background

There is confusion in the diagnosis and biological behaviors of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), because of independently proposed nomenclatures and classifications. A standardized form of pathology report is required for the proper management of patients.

Methods

We discussed the proper pathological evaluation of GEP-NET at the consensus conference of the subcommittee meeting for the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. We then verified the prognostic significance of pathological parameters from our previous nationwide collection of pathological data from 28 hospitals in Korea to determine the essential data set for a pathology report.

Results

Histological classification, grading (mitosis and/or Ki-67 labeling index), T staging (extent, size), lymph node metastasis, and lymphovascular and perineural invasion were significant prognostic factors and essential for the pathology report of GEP-NET, while immunostaining such as synaptophysin and chromogranin may be optional. Furthermore, the staging system, either that of the 2010 American Joint Cancer Committee (AJCC) or the European Neuroendocrine Tumor Society (ENETS), should be specified, especially for pancreatic neuroendocrine neoplasms.

Conclusions

A standardized pathology report is crucial for the proper management and prediction of prognosis of patients with GEP-NET.

Citations

Citations to this article as recorded by  
  • Analysis of Prognostic Risk Factors of Endoscopic Submucosal Dissection (ESD) and Curative Resection of Gastrointestinal Neuroendocrine Neoplasms
    Yuan Si, ChaoKang Huang, JingBin Yuan, XianHui Zhang, QingQiang He, ZhiJin Lin, Ling He, ZhongXin Liu, Yuvaraja Teekaraman
    Contrast Media & Molecular Imaging.2022; 2022: 1.     CrossRef
  • Standardization of the pathologic diagnosis of appendiceal mucinous neoplasms
    Dong-Wook Kang, Baek-hui Kim, Joon Mee Kim, Jihun Kim, Hee Jin Chang, Mee Soo Chang, Jin-Hee Sohn, Mee-Yon Cho, So-Young Jin, Hee Kyung Chang, Hye Seung Han, Jung Yeon Kim, Hee Sung Kim, Do Youn Park, Ha Young Park, So Jeong Lee, Wonae Lee, Hye Seung Lee,
    Journal of Pathology and Translational Medicine.2021; 55(4): 247.     CrossRef
  • Preoperative diagnosis of well‐differentiated neuroendocrine tumor in common hepatic duct by brush cytology: A case report
    Jiwoon Choi, Kyong Joo Lee, Sung Hoon Kim, Mee‐Yon Cho
    Diagnostic Cytopathology.2019;[Epub]     CrossRef
  • Primary renal well-differentiated neuroendocrine tumors: report of six cases with an emphasis on the Ki-67 index and mitosis
    Bohyun Kim, Han-Seong Kim, Kyung Chul Moon
    Diagnostic Pathology.2019;[Epub]     CrossRef
  • Primary low-grade neuroendocrine carcinoma of the skin: An exceedingly rare entity
    Tiffany Y. Chen, Annie O. Morrison, Joe Susa, Clay J. Cockerell
    Journal of Cutaneous Pathology.2017; 44(11): 978.     CrossRef
  • Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors
    Jae Hee Cho, Ji Kon Ryu, Si Young Song, Jin-Hyeok Hwang, Dong Ki Lee, Sang Myung Woo, Young-Eun Joo, Seok Jeong, Seung-Ok Lee, Byung Kyu Park, Young Koog Cheon, Jimin Han, Tae Nyeun Kim, Jun Kyu Lee, Sung-Hoon Moon, Hyunjin Kim, Eun Taek Park, Jae Chul Hw
    Pancreas.2016; 45(7): 941.     CrossRef
  • Early diagnosis and treatment of gastrointestinal neuroendocrine tumors
    Hong Shen, Zhuo Yu, Jing Zhao, Xiu-Zhen Li, Wen-Sheng Pan
    Oncology Letters.2016; 12(5): 3385.     CrossRef
  • Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
    Joo Young Kim, Seung-Mo Hong
    Archives of Pathology & Laboratory Medicine.2016; 140(5): 437.     CrossRef
  • Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade
    Koji Takumi, Yoshihiko Fukukura, Michiyo Higashi, Junnichi Ideue, Tomokazu Umanodan, Hiroto Hakamada, Ichiro Kanetsuki, Takashi Yoshiura
    European Journal of Radiology.2015; 84(8): 1436.     CrossRef
  • Tumeurs neuroendocrines du tube digestif et du pancréas : ce que le pathologiste doit savoir et doit faire en 2014
    Jean-Yves Scoazec, Anne Couvelard
    Annales de Pathologie.2014; 34(1): 40.     CrossRef
  • Spectrum of Gastroenteropancreatic NENs in Routine Histological Examinations of Bioptic and Surgical Specimen: A Study of 161 Cases Collected from 17 Departments of Pathology in the Czech Republic
    Václav Mandys, Tomáš Jirásek
    Gastroenterology Research and Practice.2014; 2014: 1.     CrossRef
  • p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors
    Hee Sung Kim, Hye Seung Lee, Kyung Han Nam, Jiwoon Choi, Woo Ho Kim
    Cancer Research and Treatment.2014; 46(4): 383.     CrossRef
Early Colorectal Epithelial Neoplasm in Korea: A Multicenter Survey of Pathologic Diagnosis
Yun Kyung Kang, So-Young Jin, Mee Soo Chang, Jung Yeon Kim, Gyeong Hoon Kang, Hye Seung Lee, Jin Hee Sohn, Ho Sung Park, Kye Won Kwon, Mi Jin Gu, Young Hee Maeng, Jong Eun Joo, Haeng Ji Kang, Hee Kyung Kim, Kee-Taek Jang, Mi Ja Lee, Hee Kyung Chang, Joon Mee Kim, Hye Seung Han, Won Ae Lee, Yoon Jung Choi, Dong Wook Kang, Sunhoo Park, Jae Hyuk Lee, Mee-Yon Cho
Korean J Pathol. 2013;47(3):245-251.   Published online June 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.3.245
  • 8,638 View
  • 54 Download
  • 1 Citations
AbstractAbstract PDF
Background

The incidence of early colorectal epithelial neoplasm (ECEN) is increasing, and its pathologic diagnosis is important for patient care. We investigated the incidence of ECEN and the current status of its pathologic diagnosis.

Methods

We collected datasheets from 25 institutes in Korea for the incidence of colorectal adenoma with high grade dysplasia (HGD) and low grade dysplasia in years 2005, 2007, and 2009; and early colorectal carcinoma in the year 2009. We also surveyed the diagnostic terminology of ECEN currently used by the participating pathologists.

Results

The average percentage of diagnoses of adenoma HGD was 7.0%, 5.0%, and 3.4% in years 2005, 2007, and 2009, respectively. The range of incidence rates of adenoma HGD across the participating institutes has gradually narrowed over the years 2005 to 2009. The incidence rate of early colorectal carcinoma in the year 2009 was 21.2%. The participants did not share a single criterion or terminology for the diagnosis of adenoma HGD. The majority accepted the diagnostic terms that distinguished noninvasive, mucosal confined, and submucosal invasive carcinoma.

Conclusions

Further research requirements suggested are a diagnostic consensus for the histopathologic diagnosis of ECEN; and standardization of diagnostic terminology critical for determining the disease code.

Citations

Citations to this article as recorded by  
  • Diminutive and Small Colorectal Polyps: The Pathologist's Perspective
    Yun Kyung Kang
    Clinical Endoscopy.2014; 47(5): 404.     CrossRef
DPC4 Expression in the Small Intestinal Adenocarcinomas
Sun Jae Lee, Eunsil Yu, Young Kyung Bae, Kee-Taek Jang, Joon Mee Kim, Han-Ik Bae, Seung-Mo Hong, Ghil Suk Yoon
Korean J Pathol. 2012;46(5):415-422.   Published online October 25, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.5.415
  • 6,163 View
  • 45 Download
  • 1 Citations
AbstractAbstract PDF
Background

Small intestinal adenocarcinomas (SACs) are rare malignancies of the alimentary tract with uncertain carcinogenesis.

Methods

We investigated the expression of deleted in pancreatic cancer 4 (DPC4) in 188 cases of surgically resected SACs, using tissue microarray technology.

Results

Twenty-four of the 188 tumors showed complete loss of Smad4/DPC4 expression in cytoplasm (score, 0; 12.8%). Eighty-four and 31 cases were moderately and strongly positive, respectively (score, 2 and 3; 44.7% and 16.5%, respectively) and 49 cases were focally or weakly stained (score, 1; 29.1%). Immunohistochemistry analysis showed that the expression of Smad4/DPC4 was related to an increased risk of lymphatic invasion but not to other clinicopathological features of the tumors (tumor location, differentiation, growth pattern, T stage, direct invasion, vascular invasion, and nodal metastasis). There was no significant association between Smad4/DPC4 expression and patient survival.

Conclusions

The present research is the first study to evaluate Smad4/DPC4 expression in a large sample of SACs with clinicopathologic correlation. Future studies should focus on the immunohistochemical and molecular characteristics of SACs to clarify their tumorigenesis.

Citations

Citations to this article as recorded by  
  • American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies
    Andrew M. Bellizzi, Elizabeth A. Montgomery, Jason L. Hornick
    Annals of Diagnostic Pathology.2020; 44: 151419.     CrossRef
WITHDRAWN:A Clinicopathologic Study of 220 Cases of Pulmonary Sclerosing Pneumocytoma in Korea: A Nationwide Survey
Myunghee Kang, Seung Yeon Ha, Joung Ho Han, Mee Sook Roh, Se Jin Jang, Hee Jin Lee, Heae Surng Park, Geon Kook Lee, Kyo Young Lee, Jin-Haeng Chung, Yoo Duk Choi, Chang Hun Lee, Lucia Kim, Myoung Ja Chung, Soon Hee Jung, Gou Young Kim, Wan-Seop Kim
Received April 4, 2018  Accepted July 9, 2018  Published online July 16, 2018  
DOI: https://doi.org/10.4132/jptm.2018.07.10    [Accepted]
  • 4,513 View
  • 63 Download

JPTM : Journal of Pathology and Translational Medicine